Category: Articles

Electrochemical bandages (e-bandages) that contain hydrogen peroxide could be an effective alternative to antibiotics when managing wound infections, according to a presentation at ASM Microbe 2022, the annual meeting of the American Society for Microbiology held in Washington, DC (abstract 2281) … Researchers from Mayo Clinic and Washington State University conducted experiments in mice. They created wounds on mice and infected them with methicillin-resistant Staphylococcus aureus (MRSA) to establish wound MRSA biofilms … read more

A prospective, randomized controlled trial

 

Chitang J. Joshi MD,Miguel Carabano MD,Laura C. Perez MD,Peter Ullrich,Abbas M. Hassan MD,Rou Wan MD,Jing Liu MD,Rachna Soriano DO,Robert D. Galiano MD, FACS

 

The Fluid Immersion Simulation system (FIS) has demonstrated good clinical applicability. This is the first study to compare surgical flap closure outcomes of FIS with an Air-Fluidized Bed (AFB), considered as standard of care. The success of closure after 14 days post-op was the primary endpoint. Secondary endpoints were incidences of complications in the first two weeks after surgery and the rate of acceptability of the device. 38 subjects were in the FIS group while 42 subjects were placed in the AFB group. Flap failure rate was similar between groups (14% vs 12%; P= 0.84). Complications, notably dehiscence and maceration, were significantly higher in the FIS group (40% vs 17%; P=0.0296). The addition of a microclimate regulation device … read more

Jarrod Shapiro, DPM, FACFAS, FACPM, FFPM, RCPS Glasg

 

Recently, I had the pleasure to take my first real vacation since the pandemic started. Three years is definitely long enough to wait for a fun trip! But being on vacation had me wondering if a short time off is actually beneficial? Do vacations improve health? Or are we fooling ourselves into thinking short breaks from work do anything to improve long-term health? Let’s see what the research tells us … read more

PLANO, Texas, June 6, 2022 /PRNewswire/ — Non-healing diabetic foot wounds are increasing in prevalence, and create a higher risk for infection, osteomyelitis and amputation. To facilitate appropriate wound healing processes, proper debridement of the wound bed is critical to remove non-viable tissue and bacterial biofilm. Traditional debridement methods involve the use of a sharp blade, a method that often results in the removal of healthy, viable tissue and pain for the patient. In contrast, the Swiss wound care company, Medaxis has developed the debritom+ to precisely clean acute and chronic wounds in a tissue-preserving manner. By using Micro Water Jet technology, the debritom+ removes the unhealthy tissue such as fibrin, necrosis, and biofilm efficiently while performing a precise mechanical cleaning and stimulation of the wound base to enhance granulation and healing.

 

Results from the interim analysis of a Multicenter Randomized Control Trial (NCT04564443) that has been accepted for presentation this week at the American Diabetes Association annual meeting in New Orleans, showed that weekly debridement using the debritom+ nearly doubled the rate of wound healing from 40% to 72% compared to the use of traditional methods. Also shown was a significant improvement in wound size reduction (87% versus 35%), while also reducing the frequency of infections and complications.

 

Study Chair, Professor David Armstrong DPM MD PhD of Keck School of Medicine of University of Southern California noted “The early data suggests great promise that better debridement tools can improve wound closure and decrease diabetic foot related complications and infections. This study supports that improved debridement methods, combined with good quality dressings and offloading, is beneficial and possibly synergistic to achieve wound healing in non-healing diabetic foot ulcers.”

 

“To initiate wound healing, a quality debridement is key to success. In contrast to traditional debridement methods that remove both the non-viable and healthy tissue, the debritom+ by Medaxis removes only the non-viable tissue while preserving the healthy tissue underneath. By creating microbleeding and providing the oxygenation to the wound that is necessary for starting the healing process, the debritom+ has now been proven to initiate healing in nearly twice as many wounds as with traditional methods with six-times fewer infections and complications” stated Dr. Mark Cregan, Managing Director of Medaxis USA.

 

Beat Moser, CEO of Medaxis said “These results validate the design philosophy of the Medaxis debritom+. The use of our patented Micro Water Jet Technology has now been proven to significantly improve wound healing outcomes. I have always believed that clean wounds heal better, and now we have the hard evidence.”

 

To view the study results, or for more information about the debritom+ by Medaxis, please see www.medaxis.us, email info@medaxis.us, or call (312) 483-6214

 

SOURCE Medaxis LLC

 

This article was originally published here

A skin biopsy is often used to diagnose skin cancer and other skin conditions … It involves the removal of a small amount of skin, which is examined under a microscope. Afterwards, you’ll need to look after the biopsy location to make sure it heals properly … Your dermatologist will treat the small wound from the skin biopsy during your visit,” said dermatologist Dr. Rajiv Nijhawan, an associate professor at UT Southwestern Medical Center in Dallas … read more

in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

 

Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI)

 

BOZEMAN, Mont. and VANCOUVER, BC, June 7, 2022 /PRNewswire/ – Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, Broad Spectrum Anti-Infective Wound Care Treatment and Prevention for Combat Injury-Related Infections”. The funding received will be used to support the conduct of an exploratory phase 2 proof of concept trial in patients hospitalized for moderate to severe diabetic foot ulcer infection with enrollment expected to begin in Q2 2022.

 

“We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. Further exploration of pravibismane’s safety and efficacy in overcoming biofilm-related DFI may potentially expand the clinical utility of topical pravibismane to treat combat wound infections in a variety of settings, including in the field and hospital.”

 

Lester Martinez, MD, MPH, Major General (Retired), U.S. Army, President and Chairman of MTEC Board commented on the importance of Microbion’s research. “Though diabetic foot ulcer infections aren’t traditionally thought of as a combat related wound suffered in the field, diabetes is a serious disease that affects a significantly high percentage of our veterans and its complications such as DFI contributes to decline in health, quality of life and are responsible for the vast majority of non-combat amputations among veterans. Microbion’s research into healing these wounds with the ultimate goal of preventing or delaying amputations can potentially improve the daily lives of these patients and return normal mobility,” Dr. Martinez stated.

 

Pravibismane is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. In in vitro studies, pravibismane exhibits broad-spectrum, potent activity against DFI-relevant pathogens and their biofilms including MRSA and drug resistant P. aeruginosa.

 

In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care demonstrated a numeric 85% wound size reduction versus 30% placebo plus standard of care. Pravibismane also demonstrated a numeric reduction in ulcer-related amputation (2.6% in the pravibismane group vs 15.4% placebo).

 

DFIs are a major health concern in the Veterans Health Administration as DFUs are associated with a substantial mortality rate (five-year mortality rates are as high as 45% for neuropathic ulcers and 55% for ischemic ulcers1) and often require amputation to fully address the nidus of infection.2 Approximately 28.5 million adults in the US are diagnosed with diabetes, of whom 15 – 25% are at risk of developing a foot ulcer.3,4 More than half of diabetic foot ulcers become infected.5 DFIs remain the most frequent diabetic complication requiring hospitalization and are the most common precipitating event leading to lower extremity amputation.6 Furthermore, recent studies suggest that many DFIs are caused by bacteria in a biofilm mode.6 In 2018, there were ~8.25 million hospital discharges with diabetes reported, including 154,000 for a lower-extremity amputation.3 US Veterans Affairs estimates there were 20.3 million living Veterans in 2018.7 The overall prevalence of diabetes among US veterans is ~25%, which is higher than the US civilian population at ~9%.8

 

References:

1. Del Core MA, Ahn J, Lewis RB, et al. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864
2. Sundararajan PP, Porter BM, Grant KA, et al. Foot infections in the Veterans Health Administration. The Foot and Ankle Online Journal. 2015;8(3):1. doi:10.3827/faoj.2015.0803.0001
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html, accessed June 6, 2022
4. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016;24(1):112–26. doi: 10.1111/wrr.12391
5. Armstrong, DG, Boulton, AJM, and Bus, SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367-75. doi: 10.1056/NEJMra1615439
6. Lipsky et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diab Metab Res Rev. 2020. e3280. doi: 10.1002/dmrr.3280
7. VETPop2018: A Brief Description. Web: https://www.va.gov/vetdata/docs/Demographics/New_Vetpop_Model/VP_18_A_Brief_Description.pdf, accessed June 6, 2022
8. Liu Y, Sayam S, Shao X, et al. Prevalence of and trends in diabetes among veterans, United States, 2005–2014. Prev Chronic Dis. 2017;14:170230. doi: 10.5888/pcd14.170230

 

About Microbion
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering unique potential to address the unmet needs of chronic and severe health conditions. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Microbion Pharma Corp. is a wholly owned subsidiary of Microbion Corporation. For more information visit: www.microbioncorp.com.

 

About CUBRC
CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. For more information visit: www.cubrc.org.

 

Safe Harbor Statement
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

US Government Funding Disclaimer
Efforts described herein were partially sponsored by the Government under Other Transactions Number W81XWH-15-9-0001. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

 

SOURCE Microbion Corporation

This article was originally published here

First time an EHR company has received Breakthrough Device Status

 

PITTSBURGH, June 2, 2022 /PRNewswire/ — Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced today that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA). Tissue Analytics received the rare designation because of its novel diagnostic algorithms. The Company believes the FDA designation represents the first time an EHR company has been granted such designation.

 

Breakthrough Status indicates that the FDA believes the Company’s novel diagnostic Software as a Medical Device (SaMD) could provide more effective treatment or diagnosis of a life-threatening or debilitating condition, such as hospital-acquired pressure injuries (HAPIs), venous and diabetic foot ulcers and other non-healing wounds. Breakthrough Status is not granted solely on the severity of the device’s applicable condition. The submission must also meet one of the following criterion: the proposed device represents “breakthrough technology” as defined by the FDA; no other approved or cleared alternatives exist; the device offers significant advantages over existing approved or cleared alternatives; or the device availability is in the patient’s best interest.

 

Net Health’s Tissue Analytics Technology Pushes the Boundaries

“Finding ways to help our clients more quickly and accurately identify potentially life-threatening wounds and manage associated costs has been a priority for more than 20 years,” said Josh Pickus, CEO of Net Health. “The FDA designation highlights that Net Health is redefining EHRs as much more than simple documentation systems. Our intelligent AI-driven analytics solutions are pushing the boundaries of EHRs and helping change healthcare outcomes.”

 

Thu, June 2, 2022, 8:00 AM·3 min read
First time an EHR company has received Breakthrough Device Status

 

PITTSBURGH, June 2, 2022 /PRNewswire/ — Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced today that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA). Tissue Analytics received the rare designation because of its novel diagnostic algorithms. The Company believes the FDA designation represents the first time an EHR company has been granted such designation.

 

(PRNewsfoto/Net Health Systems, Inc.)
(PRNewsfoto/Net Health Systems, Inc.)
Breakthrough Status indicates that the FDA believes the Company’s novel diagnostic Software as a Medical Device (SaMD) could provide more effective treatment or diagnosis of a life-threatening or debilitating condition, such as hospital-acquired pressure injuries (HAPIs), venous and diabetic foot ulcers and other non-healing wounds. Breakthrough Status is not granted solely on the severity of the device’s applicable condition. The submission must also meet one of the following criterion: the proposed device represents “breakthrough technology” as defined by the FDA; no other approved or cleared alternatives exist; the device offers significant advantages over existing approved or cleared alternatives; or the device availability is in the patient’s best interest.

 

Net Health’s Tissue Analytics Technology Pushes the Boundaries

 

“Finding ways to help our clients more quickly and accurately identify potentially life-threatening wounds and manage associated costs has been a priority for more than 20 years,” said Josh Pickus, CEO of Net Health. “The FDA designation highlights that Net Health is redefining EHRs as much more than simple documentation systems. Our intelligent AI-driven analytics solutions are pushing the boundaries of EHRs and helping change healthcare outcomes.”

 

Deployed by hundreds of healthcare organizations, including leading hospitals, health networks, and independent wound care clinics, Tissue Analytics’ novel diagnostic solution analyzes skin injury images and patient data using machine learning technology. This new level of analysis will allow Tissue Analytics to eventually provide new diagnostic elements as a complement to its current measurement generation imaging software, pending approval of its forthcoming marketing submission.

 

In granting the Breakthrough Device Status, the FDA recognized that the software could help wound care providers improve care by standardizing the diagnosis and care process of triaging patients with chronic, non-healing wounds with poor healing trajectories. In addition, the Agency noted that the “product will aid clinicians throughout the referral process with additional diagnostic information that can inform the wound care experts’ ultimate diagnosis and plan of care for chronic, non-healing wounds.”

 

“A first of its kind advancement like Tissue Analytics’ novel imaging functionality will make the clinical workflow for wound care safer, more effective, and ultimately more efficient,” said Alex Cadotte, Ph.D., ex-FDA Team Lead and now Director of Software and Digital Health at MCRA, LLC. “The FDA’s breakthrough designation acknowledges that Tissue Analytics is a first-of-its-kind device in Wound Care. The designation will also facilitate a collaborative conversation with FDA, which will ultimately be a win for public health.”

 

For more information on Tissue Analytics, visit https://www.nethealth.com/solutions/wound-care-tissue-analytics/ or https://www.tissue-analytics.com/ .

 

Net Health’s mission is to harness data for human health. Net Health solutions are trusted in over 23,000 facilities across the continuum of care. Our EHR software enables caregivers and their organizations to engage effectively with patients, streamline documentation, staff efficiently, secure maximum appropriate reimbursement and maintain regulatory compliance. Our unique approach to analytics seamlessly presents insights in clinical and operational workflows to improve care and business performance. Net Health is a portfolio company of The Carlyle Group, Level Equity and Silversmith Capital Partners. www.nethealth.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/net-healths-tissue-analytics-for-wound-care-granted-breakthrough-device-status-by-fda-301560059.html

 

SOURCE Net Health Systems, Inc.

Join us Thursday 30th June, for a clinical training session on improving hard-to-heal wounds with a specific focus on oedema and fibrosis, brought to you by Journal of Community Nursing in partnership with Thuasne.
‘Improving hard-to-heal wounds by managing oedema and fibrosis’ will be presented by Julie Stanton, Director of Nursing, Pioneer Wound Healing & Lymphoedema Centres.
You will have the opportunity to ask Julie any questions you may have during the real-time Q&A following the presentation. You will also receive a certificate of attendance upon completion of the session, which can be used towards your CPD revalidation portfolio.
Click ‘Going’ to register and receive further updates … read more

2022 is a time to heal, a time to unite and a time to innovate.

In September 2022 leading experts and delegates from around the world will come together to explore the current developments, innovations, practice and research that unite and heal at the Wounds Australia 2022 Conference.

A unique opportunity for professionals working in the field of wound management and care to participate in an exciting and challenging program. Delegates will actively engage with industry leaders and experts across a range of fields to reflect and critically assess the history of wound care, investigate current practise and the progress that has been made and explore opportunities for future innovations.

We are excited that the Wounds Australia 2022 Conference will enable delegates to reconnect, in person, after nearly two years of incredible challenges. The Conference will deliver a scientific and social program that is all about healing, uniting and innovating for the future … read more

A new study, “An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds,” published in the International Society For Pharmacoeconomics and Outcomes Research’s Value in Health journal (Jan. 2018) demonstrates the economic impact and full burden of chronic nonhealing wounds in the Medicare population. The study analyzed the Medicare 5% Limited Data Set for CY2014 to determine the cost of chronic wound care for Medicare beneficiaries in aggregate, by wound type, and by setting. Topline findings show that chronic wounds impact nearly 15% of Medicare beneficiaries (8.2 million) at an annual cost to Medicare conservatively estimated at $28.1 to $31.7 billion … read more

Abstract: Background. The evaluation and treatment of heel pressure injuries are a significant and expensive sequela of the aging population. Although the workup of patients with lower extremity tissue loss usually involves an assessment of the arterial blood flow by means of noninvasive vascular testing, the results may be misleading in patients with heel pressure injuries when the ankle-brachial index (ABI) does not provide direct information about perfusion of the rearfoot. The objective of this retrospective, observational investigation was to determine if noninvasive vascular testing provides accurate and reliable results in patients with heel pressure injuries … read more

The incidence of chronic wounds is increasing due to aging population and the augment of people afflicted with diabetes. Knowledge on the biological mechanisms underlying these diseases, there is a lot of medical technologies to conventionally treat the wound however wound healing differs from person to person … Several nanotechnologies have been developed demonstrating unique characteristics that address specific problems related to wound repair mechanisms. A review in Advance wound care journal, focused on the most recently developed nanotechnology-based therapeutic agents and evaluated the efficacy of each treatment in diabetic models … The success of topically administered growth factors in chronic wounds is limited. Due to their short in vivo half-life, low absorption rate through the outermost skin later around the wound, as well as rapid elimination by exudation before reaching the wound bed, might limit the efficacy of growth factors topical application … Conventional medications containing growth factors need to be applied in high doses and/or be repeatedly administrated over a long period, leading to important side effects and increasing the cost of the therapy. Presently, platelet-derived growth factor , fibroblast growth factor, and epidermal growth factor are widely studied for their application … read more

Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management

 

Toronto, CANADA and London, UK – (June 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced that it has been added to the new 2022 Consensus Guidelines of the International Surgical Wound Complications Advisory Panel (ISWCAP). The document, “Optimising Prevention of Surgical Wound Complications: Detection, Diagnosis, Surveillance and Prediction”1 presents an international consensus recommending approaches for the early detection, diagnosis and prediction of surgical wound complications in order to optimise incisional wound healing outcomes for patients.

 

Surgical wound complications remain a significant challenge for clinicians around the globe, representing one of the leading global causes of morbidity following surgery. The incidence of surgical wound complications, including surgical site infections (“SSI”), continues to rise. The development of a SSI is associated with a marked increase in morbidity, a 2-to 11-fold increase in mortality rate, and prolonged hospital stays2. Approximately 2-5% of surgical wounds in the US develop a SSI3 – 6 at an annual cost of up to $10 billion6-9. This includes extended hospital stays, readmissions and additional resources to manage complications.

 

In the consensus guidelines, the ISWCAP expert group noted that “the role of diagnostic technology is of particular importance in identification of surgical wound complications as it provides an objective means of detecting infection or another surgical wound complication without having to rely on clinician judgement – i.e. it helps to remove the subjective ‘human factor’ from identification and diagnosis”10.

 

MolecuLight’s point-of-care fluorescence imaging system is identified in the consensus because of its proven utility to quickly and non-invasively identify surgical site infections:

The ISWCAP expert group agreed that point-of-care fluorescence imaging is a diagnostic technology that could be of significant benefit in early identification of surgical site infections and may be a useful tool for early detection of other surgical wound complications10

 

The consensus also notes how fluorescence imaging is being used to guide detection of pathogenic activity and is providing useful insights and potentially changing current clinical assessment and diagnosis paradigms.11 Numerous studies have established the utility of the MolecuLight point-of-care technology in chronic wounds12, 13 (Le et al, 2020; Price, 2020). “The use of this technology in detection of SSI is an emerging field showing promising results”, notes the consensus. An example is “a recent study, ’Uncovering the high prevalence of bacterial burden in surgical site wounds with point-of-care fluorescence imaging’14, illustrated an 11-fold sensitivity in detection of infection by the MolecuLight device compared to clinical signs and symptoms alone (Sandy-Hodgetts et al, 2021)”.11

 

“Due to its ability to quickly and reliably detect bacterial burden at the point-of-care, fluorescence imaging using the MolecuLight device is positioned to change contemporary paradigms of post-surgical wound management”, says lead author Kylie Sandy-Hodgetts, PhD, Founder and inaugural President of the ISWCAP. “Early detection and prevention of surgical wound complications, including SSIs, are the ISWCAP’s key areas of focus. Novel diagnostic technology for earlier detection and intervention is imperative to optimise surgical wound outcomes. MolecuLight’s point-of-care fluorescence imaging of critical bacterial burden is at the forefront of that much needed initiative.”

 

References:

1Sandy-Hodgetts K et al, “Optimising prevention of surgical wound complications: Detection, diagnosis and prediction”, Wounds Intl., 2022
2Hatch MD et al. J Shoulder Elbow Surg. 2017;26(3):472-4777 3 Ban KA et al. J Am Coll Surg. 2017;224(1):59-74
4 Berrios-Torres SI et al. JAMA Surg. 2017;152(8):784-791 5 Institute CPS. Canadian Surgical Site Infection Prevention Audit. 2016 6 Si D et al. BMC Infect Dis. 2014;14:318
7 Badia JM, et al. J Hosp Infect. 2017;96(1):1-15
8 McLaws ML et al. J Hosp Infect. 2003;53(4):259-267
9 Sullivan E et al. Surg Infect (Larchmt). 2017;18(4):451-454 10 Sandy-Hodgetts K et al, Wounds International, 2022, pp. 9
11Sandy-Hodgetts K et al, Wounds International, 2022, pp. 16
12 L. Le, Advances in Wound Care, 25 Sep 2020 13N. Price, Diagnostics, 2020
14 Sandy Hodgetts, K. et al., Int Wound J. 2021;1–11.

 

About MolecuLight Inc.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

For more information, contact:
Rob Sandler
Chief Marketing Officer
MolecuLight Inc. T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

 

Image (Download): https://moleculight.box.com/s/4tsj23g59tsesh8uwgnbhoow5aikbrjz

The pipeline for wound healing technologies includes lasers that kill bacteria and fluorescence imaging to aid in diagnostics.

 

FREMONT, CA: A skin wound is typically considered to be of little concern to the average person; however, a variety of disorders can cause or contribute to the severity of a wound that necessitates the use of specific technologies for proper healing.

Patients are predisposed to chronic wounds due to underlying factors ranging from malnutrition and stress to metabolic syndrome, necessitating intervention to accelerate a sluggish healing process.

In the United States, 3 percent of the population over the age of 65 has open wounds, and 2 percent of the entire population suffers from chronic wounds, according to a recent scholarly article that examined the magnitude of the problem.

Medicare cost forecasts for all wounds, including costs for infection treatment, range from $28.1 billion to $96.7 billion, with surgical wounds and diabetic ulcers being the most expensive to treat … read more

Treatment with the experimental protein replacement therapy PTR-01 promoted wound healing and decreased pain in people with recessive dystrophic epidermolysis bullosa (RDEB), new results from a Phase 2 clinical trial show.

The findings were presented by BridgeBio Pharma and its affiliate, Phoenix Tissue Repair, the therapy’s developer, at the annual meeting of the Society for Investigative Dermatology, in Portland, Oregon in May.

“In patients with recessive dystrophic epidermolysis bullosa (RDEB) even minor friction or trauma can cause debilitating blistering, tearing and scarring of the skin, along with severe pain … read more

Advancements in technology has helped healthcare enterprises deliver better wound care over the past few years.

 

Long-term care (LTC) wound management can provide a number of problems in achieving the ultimate aim of complete wound healing. Pressure ulcers, ischemic ulcers, venous ulcers, and diabetic foot (neuropathic) ulcers are all common conditions that healthcare providers see and treat. The risk of developing an ulcer should be examined in all residents. If a person is at high risk for developing an ulcer, staff should take aggressive measures such as nutritional support or pressure reduction. If an ulcer forms, the main goal is to heal it fully as soon as feasible and at a fair cost. Providers should distinguish between pressure, ischemia, venous, and neuropathic ulcers, keeping in mind that they might be combined and contain two or more components. Providers should assure appropriate foundational care, adequate nutrition, proper blood supply, edoema control, and great topical wound care in order to attain this goal. Topical wound care promotes wound healing by moisturizing the area and reducing necrotic tissue … read more

Researchers at the Technical University of Munich (TUM) have developed a film that not only protects wounds similar to the way a bandage does, but also helps wounds to heal faster, repels bacteria, dampens inflammation, releases active pharmaceutical ingredients in a targeted manner and ultimately dissolves by itself. This is all made possible by its dedicated design and the use of mucins, molecules which occur naturally in mucous membranes … read more

Diabetic foot ulcers (DFUs) are open sores or wounds caused by a combination of factors that include neuropathy (lack of sensation), poor circulation, foot deformities, friction or pressure, trauma, and duration of diabetes with complication risks. DFUs occur in 34% of people with diabetes,1 and approximately 14% to 24 % of patients with diabetes who develop a DFU will require an amputation … Diabetic complications cause 40% to 60% of nontraumatic lower limb amputations worldwide, and 80% of these amputations follow DFUs.2 However, a DFU is a preventable condition, despite being the leading cause of nontraumatic lower extremity amputations in the United States … read more

The role of wound cleansing in the management of wounds

 

This 30-minute presentation features learning opportunities that will provide in-depth instruction and demonstration in wound care treatments. After this webinar, the learner will be able to:

Identify the role of proper wound cleansing
Discuss how to select and use non-toxic wound cleansers
Describe advantages of collagen for managing a chronic wound
… read more

Researchers from the University of Tsukuba show that antibiotic resistance can be transferred between Staphylococcus bacteria by a process known as natural transformation … A bacteria called Staphylococcus aureus is widespread and generally harmless, but can cause infections known as “opportunistic infections”. These occur when the bacteria take advantage of certain situations, such as a weakened immune system or the presence of an open wound, to cause a harmful infection. These infections become particularly dangerous when the bacterial strain is resistant to treatment with antibiotics. Strains of Staphylococcus aureus known as MRSA, which are resistant to an antibiotic called methicillin, are becoming a significant problem worldwide. Now, a team from the University of Tsukuba have revealed the mechanism by which this methicillin resistance can be passed between bacteria … read more

providing the highest quality human tissue allografts available. We demonstrate our commitment to quality by collecting data from patient outcomes and analyzing the data for statistical significance, ensuring physicians make the most informed decision for the health of their patients. With the goal of addressing the root cause, rather than masking the pain, Regenative Labs birth tissue allografts provide an effective, non-addictive, non-invasive option for patients in debilitating situations.

 

Submit your contact information below and a representative will reach out shortly. Are you ready to create a new account? Click here to signup (please list Wound Care Weekly in the distributor field).

 

• Diabetic foot ulcers (DFU) are chronic wounds in the foot or feet associated with neuropathy and/or peripheral artery disease (PAD) of the lower limb in patients with diabetes mellitus.
• Reports from the Centers for Disease Control and Prevention show that in the United States there are nearly one in four adults living with diabetes, which indicates that a large number of Americans are at risk of DFU.
• DFUs will develop in up to 34% of patients with diabetes at some time in in their lives, and of those, approximately 15%–25% will require an amputation.
• Moderate or severe malnutrition has been identified in over half of patients with DFU, and malnutrition in DFU is correlated with increased lower-extremity amputation.
• Improvements in wound care therapy, including nutrition interventions, can reduce the financial burden of DFUs and increase life expectancy and quality of life.

… read more

BY BECKY DEY – from OCTOBER 2018

 

A wound dressing made from the silk protein sericin can help skin recover without scar tissue forming, new research shows … Millions of people worldwide suffer serious skin wounds caused by burns or trauma that are unable to self-heal. The main complication surrounding skin regeneration is scar tissue, which has different functional and mechanical properties to normal physiological tissue, often causing pain and discomfort for those affected … read more

Building on the previous success of education and awareness activities, Hamad Medical Corporation (HMC) recently joined the American Diabetic Awareness Alert Day to promote Diabetic Limb Salvage and launch a nationwide Awareness Campaign themed ‘Early diagnosis leads to early intervention: save a leg, save a life’ … The initiative was aimed at educating the general public and specifically diabetic patients at risk of feet ulcers and leg amputation, increasing their knowledge of signs and symptoms of this disease, and encouraging them to take care of their own feet … Diabetic foot is a substantial public health issue that affects people worldwide. Statistics show that twenty-five percent of people with diabetes are at risk of developing diabetic foot ulcers (DFUs). Limb salvage is the endeavour to save a limb from amputation, such as the foot … read more

BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022 between May 18 – 21, 2022 in Portland, Oregon … read more

GREENVILLE, S.C., May 18, 2022 /PRNewswire/ — A revolutionary temperature and pressure (TAP) sensing insole for diabetics, created by XtremedX, was recently named a TOP 20 New Diabetic Device for 2022 by the Diabetes Center Berne (DCB) in Berne, Switzerland. This is an international competition with the winners chosen by a panel of judges who are leading experts in diabetes care. XtremedX’s TAP sensing insole was one of only two products selected from the US as a leading innovative device for the management of diabetes.

 

Failure to heal a diabetic foot ulcer is a leading cause of hospitalization, amputation, disability, and death among people with diabetes. XtremedX TAP sensing insole for diabetics helps with daily monitoring of the feet, which can reduce diabetic foot ulcers by up to 85%. The sensor detects differences over time between both feet. Accumulated data from the sensor is then sent to the patient, caregiver, and/or physician via Bluetooth, Wi-Fi, or cellular technology for monitoring. An alert is provided by the insole at the first sign that an ulcer could potentially develop – often 4-6 weeks before the onset of symptoms. This allows the patient to take preventative measures to avoid an ulcer or further complications including amputation of lower extremities.

 

“We’re honored that we’ve been selected by the Diabetes Center Berne for this innovation challenge among all of the other incredible ideas and inventions to improve diabetes care,” said Carl Marshbanks, CEO of XtremedX. “It’s been an exciting time for our team, as we also recently were recognized as a first-place winner of the WeaRAcon 2022 international wearable robotics association conference this year. We’ve set out to create a product that will truly impact the management of diabetes and we’re glad to see that leaders in our industry believe in our mission as well.”

 

Each of the 20 companies with devices selected by Diabetes Center Berne participated in a pitch round this May where they presented their devices to a panel of DCB judges. These judges will select the top three finalists to participate in a bootcamp taking place on June 20 – 24 in Switzerland to develop their ideas with the help of the experts at DCB. After the bootcamp, a winner will be chosen on November 30 to be awarded $100,000 to fund further development of their innovation.

 

Diabetes Center Berne was created to advance diabetes care by bringing together some of the world’s leading experts to drive thought and innovation and provide access to clinical research facilities, laboratories, workspaces, and financial resources. Their innovation challenge provides an opportunity for companies with forward thinking ideas from around the world to make the greatest impact on the future of diabetes management.

 

ABOUT XTREMEDX

XtremedX LLC strives to develop the most technically advanced products, improving the quality of patient’s lives. They innovate technologically advanced products for Orthopedics, Surgery, DME (Durable Medical Equipment), and Smart Sensor Technology. Their mission is to create products that help to improve patient outcomes and reduce overall health care costs. As a Top Biomechanics Solutions Provider of 2021, they are also named a TOP 20 New Diabetic Device for 2022 by the Diabetes Center Berne, and a recipient of first-place award at the international wearable robotics association conference, WeaRAcon 2022. For more information, please visit www.xtremedx.com.

 

ABOUT DIABETES CENTER BERNE

Diabetes Center Berne is a private, independent Swiss foundation established in 2017. It helps research projects and business ideas to grow. Based in Switzerland, DCB provides expertise, access to clinical research facilities and its own laboratories and workspaces, and funding to projects around the world. It is located on the Insel Campus in the Swiss capital Bern. DCB works in close scientific partnership with the Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism of the Inselspital Bern (UDEM), a university hospital with a stellar international reputation in the field of diabetes technology.

 

Diabetes Center Berne
Freiburgstrasse 3
CH-3010 Bern
www.dcberne.com

 

SOURCE XtremedX

This article was originally published here

Longtime Congresswoman and former President and CEO of the Better Medicare Alliance, Allyson Schwartz, also joins Podimetrics’ Advisory Board

 

SOMERVILLE, Mass., May 12, 2022 /PRNewswire/ — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced four new leadership hires aimed at helping the company scale and support even more health plans and providers serving patients living with complex diabetes: Matthew Scalo as Chief Financial Officer, Kyle Bray as Chief Operating Officer, Kim Nguyen as Vice President of Financial Planning and Analysis, and Elizabeth Hogan Hamacher as Vice President of Clinical Services and Support. Podimetrics also added a new member to their advisory board, Allyson Schwartz, a long-time Congresswoman and also the former President and CEO of the Better Medicare Alliance.

 

These key hires and advisory board appointment follow Podimetrics’ recent announcement of their Series C. The company also experienced unprecedented growth in 2021, including doubling the patients under management with the Veterans Health Administration; doubling revenue for the third year in a row; and also doubling the size of the Podimetrics team. Dr. Jon Bloom, CEO and co-founder of Podimetrics, shared the following insights on the company’s growth trajectory for the year ahead: “We are in high-growth mode, and these leadership hires and the appointment of Allyson Schwartz to Podimetrics’ advisory board reinforce our focus on helping even more at-risk, underserved patients avoid the unnecessary health toll and financial burden associated with amputations resulting from complex diabetes.”

 

In just the first quarter of 2022, Podimetrics rounded out their leadership team with a series of strategic new hires that position the company for strong growth in the year ahead:

 

• Matthew Scalo, Chief Financial Officer — With nearly two decades of experience spanning banking and financial services, he most recently served as the senior vice president of finance at Cancer Treatment Centers of America;
• Elizabeth Hogan Hamacher, Vice President of Clinical Services and Support — A registered nurse with more than 12 years of clinical operations experience, she most recently served as senior director of clinical operations at ConsumerMedical; and
• Kim Nguyen, Vice President of Financial Planning and Analysis — With more than a decade of experience, she most recently served as associate vice president for financial planning and analysis for vRad (Virtual Radiologic).

 

The company’s latest addition to their advisory board, Allyson Schwartz, also brings unprecedented experience in healthcare, as well as policy. As a former member of the House of Representatives and former President and CEO of the Better Medicare Alliance, she is a nationally recognized leader on healthcare issues and was also instrumental in the passage of the Affordable Care Act. Schwartz shared the following insights about joining the advisory board at Podimetrics: “Podimetrics serves some of our nation’s most vulnerable patients — patients who have been ignored for far too long. It’s an honor to join their advisory board. The research and innovation they are leading will help drive a new preventive and proven approach to helping reduce amputations in patients living with complex diabetes.”

 

Podimetrics invented the SmartMat, which has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans. The SmartMat is the only easy-to-use, at-home mat that a patient steps on for only 20 seconds per day. The mat detects temperature changes in the foot, which are often a precursor to diabetic foot ulcers (DFUs). Patient temperature data from the SmartMat is then remotely monitored by Podimetrics’ in-house nurse support team. If the data from the mat is indicative of potential health issues, Podimetrics’ nursing team swiftly connects both with the patient and the patients’ provider.

 

For more information on Podimetrics and how its SmartMat and clinical care services can help prevent diabetic foot ulcers and improve patient outcomes, please visit Podimetrics.com.

 

About Podimetrics

Podimetrics is the creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex diabetic patients. Through partnerships with regional and national health plans and at-risk providers, such as the Veterans Health Administration, Podimetrics has helped prevent amputations associated with complex diabetes. By combining cutting-edge technology with best-in-class clinical care services, Podimetrics earns high engagement rates from patients and allows clinicians to save limbs, lives, and money — all while keeping vulnerable populations healthy in their own homes. For more information, visit Podimetrics.com or follow us on LinkedIn and Twitter.

Contact: press@Podimetrics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/podimetrics-announces-expansion-of-leadership-team-with-four-new-strategic-growth-hires-301545591.html

BY LEONARD A. LEVY, DPM, MPH (from April 2021)

 

Podiatric Medical Practice, People with Diabetes, and the Relationship to Primary Care The typical practice of podiatric medicine includes a population that receives care on a more frequent basis than perhaps most patients seen by other medical specialists (e.g. surgeon, ophthalmologist, dermatologist, and otorhinolaryngologist). Patients who receive care from podiatric physicians very often do so several times yearly and often follow such a regimen over several years. Because of this, podiatric physicians with their education and training appropriately could be among the physicians who provide a major segment of primary care … read more (PDF)

Nancy Collins, PhD, RDN, LD, NWCC, FAND

 

Nutrition is a critical factor in the wound healing process, with adequate protein intake essential to successful healing. Patients with chronic and acute wounds, such as postsurgical wounds or pressure injuries, require increased protein to ensure complete and timely healing. Older patients with multiple comorbidities present a particular challenge. They often do not consume the necessary quality and quantity of dietary protein. In addition, this population may have a heightened stress response and resultant muscle loss due to a reduction in muscle protein synthesis. The all too frequent result is compromised wound healing, decreased ability to fight infections, and longer recovery time from illnesses and surgeries. It is imperative to address the increased protein needs of patients with wounds, especially older patients, to promote a full recovery … read more

“Uncaring: How the Culture of Medicine Kills Doctors and Patients”

 

by Caroline Fife, M.D.

 

I’ve been venting about my experiences with a broken healthcare system – both as a doctor and a caregiver. My friend, colleague, plastic surgeon and Renaissance man, Dr. Aron D. Wahrman alerted me to Robert Pearl’s book, Uncaring: How the Culture of Medicine Kills Doctors and Patients (a follow up to his book, Mistreated: Why We Think We’re Getting Good Health Care — and Why We’re Usually Wrong. I’ve recently talked about the experience of my friend and patient Dr. Richard Maddy, who lost both of his legs to cutaneous polyarteritis nodosa– in part because my pleas to start high dose steroids based on his clinical presentation were ignored, and my husband who died (albeit indirectly) from an adverse drug reaction that I diagnosed but for whom I could not the proper intervention from his inpatient team … read more

Author(s): Thomas Bjarnsholt, Val Edwards-Jones, Matthew Malone, Karen Ousey, Mark Rippon, Alan Rogers, Samantha Westgate, Sabine Eming, Isabelle Fromantin, Astrid Probst, Hans Smola, Hui-Mei Yang, Jiun-Ting Yeh, Steven Percival

 

Every wound type has the potential to develop serious infection, which in some cases can lead to chronicity, bone infections, long-term disabilities or even death. Bacteria within a wound will exist in either planktonic or biofilm forms, with treatment mostly by use of topical antimicrobials or antibiotics. Alarmingly, there is growing concern regarding the treatment of infection, caused by the rise of antimicrobial resistance in many common bacterial pathogens and the misuse of antimicrobial agents … read more

Chronic wound caused by diabetes is an important cause of disability and seriously affects the quality of life of patients. Therefore, it is of great clinical significance to develop a wound dressing that can accelerate the healing of diabetic wounds. Nanoparticles have great advantages in promoting diabetic wound healing due to their antibacterial properties, low cytotoxicity, good biocompatibility and drug delivery ability. Adding nanoparticles to the dressing matrix and using nanoparticles to deliver drugs and cytokines to promote wound healing has proven to be effective. This review will focus on the effects of diabetes on wound healing, introduce the properties, preparation methods and action mechanism of nanoparticles in wound healing, and describe the effects and application status of various nanoparticle-loaded dressings in diabetes-related chronic wound healing … read more

‘Best Technology Award’ and ‘Best Newcomer Award’

 

PRESS RELEASE MAY 10, 2022

DALLAS, May 10, 2022 (Newswire.com) – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, has been recognized for two prestigious European technology awards.

 

Spectral MD has been shortlisted for two awards at this year’s European Mediscience Awards for:

Best Technology Award
Best Newcomer Award

 

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognizing achievements in the life sciences industry. The European Mediscience Awards recognizes success and achievement amongst both private and publicly quoted companies throughout Europe and, as such, is attended by European life science companies and their corporate advisers, analysts, fund managers, commentators and peers.

 

Nooman Haque, Managing Director, Lifescience & Healthcare, Silicon Valley Bank, commented:

“The shortlist reflects the continuing strong growth of the European Mediscience industry and, in these challenging economic times, highlights those companies best positioned to manage through the turbulent cycle. We’re delighted to see such continuing enthusiasm for the industry.”

 

Wensheng Fan, CEO of Spectral MD, said:

“We are honored that Spectral MD has received nominations for ‘Best Technology Award’ and ‘Best Newcomer Award.’ This recognition further validates the promising potential of our DeepView® Wound Imaging Technology. DeepView® has the potential to be transformative in wound care. We look forward to building on this support and the exceptional results obtained thus far to expand into other important indications for our artificial intelligence for wound healing diagnostics.”

 

The winners will be announced at the celebratory dinner, to be held at the Hotel InterContinental, London W1, on Thursday, June 16, 2022.

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown”® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

Both Planktonic Bacteria and Bacterial Biofilms

 

Highlights

• In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log reductions in planktonic (free-floating) bacteria and 4-log to 8-log reductions in biofilm bacteria (colonies of bacteria)
• XPERIENCE was shown to inhibit biofilm formation for up to five hours after application
• Study published in The Journal of Arthroplasty

 

JACKSONVILLE, Fla.–(BUSINESS WIRE)–Next Science Limited (ASX:NXS) (Next Science / the Company) is pleased to report that XPERIENCE™ No Rinse Solution has been shown to have persistent efficacy against both planktonic bacteria and bacterial biofilms in a new study published in The Journal of Arthroplasty. The study, “A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty,” also found that XPERIENCE produced minimal cytotoxic effects to human tissue, allowing the solution to remain in the body without need for subsequent rinse. Additionally, XPERIENCE – cleared by the FDA for U.S. sale in April 2021 – was shown to inhibit biofilm formation for up to five hours after application.

 

Prosthetic joint infection (PJI) remains a significant burden in total hip arthroplasty (THA) and total knee arthroplasty (TKA) in the United States. Estimates indicate that, by 2030, the annual hospital costs related to PJI of the hip and knee will be $1.85 billion.1 Interventions to reduce or prevent the occurrence of PJI continue to be at the forefront of research efforts and commercial development.

 

“The minimum standard of care for irrigation in orthopedic surgical cases includes normal saline, but an increasing amount of literature in recent years has suggested that different solutions or additives may be needed to prevent PJI,” said orthopedic surgeon Ravi K. Bashyal, MD, the study’s lead author. “Combatting planktonic bacteria and the formation of biofilm is especially important given the high negative consequence of developing a PJI in the total joint arthroplasty setting.”

 

In the in vitro study, XPERIENCE demonstrated 4-log to 6-log reductions in planktonic bacteria after five minutes, and 4-log to 8-log reductions in biofilm bacteria. Future research using large-series in vivo data is necessary to further establish the irrigant’s efficacy in reducing primary and recurrent surgical site infections (SSIs). An estimated 1.5 million SSIs in the United States each year2 contribute $3.3 billion to the cost of U.S. healthcare.3

 

The study also found that XPERIENCE showed higher in vitro antimicrobial efficacy than three other commercially available adjuvants. The comparative treatments each reduced biofilm in all bacterial strains tested by approximately 1-log or less when the application times in their respective instructions for use were followed. However, XPERIENCE reduced biofilm by approximately 3-log to 8-log when used as directed.

 

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center in Florida, USA. Established in 2012, the Company’s primary focus is on the development and continued commercialization of products powered by its proprietary XBIO Technology. For further information visit: www.nextscience.com.

 

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science’s actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

 

¹Premkumar A., Kolin D.A., Farley K.X., et al. “Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States.” J Arthroplasty, 2021;36(5):1484-1489 e1483.

²Darouiche, R. (2019). “Surgical Site Infections.” Retrieved from: https://www.infectiousdiseaseadvisor.com/home/decision-support-in-medicine/ hospital-infection-control/surgical-site-infections

³Zimlichman, E., et al. “Health Care-Associated Infections. A Meta-Analysis of Costs and Financial Impact on the US Health Care System.” JAMA Intern Med, 173(22): (2013): 2039-46.

 

Contacts
Judith Mitchell
Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

 

Anthony Priwer
Dalton Agency
Phone: +1 615-515-4891
Email: apriwer@daltonagency.com

Hidradenitis suppurativa (HS) is a chronic autoinflammatory disease characterised by recurrent painful nodules, abscesses, sinus tracts and scars at apocrine gland-bearing sites. Treatment is universally challenging and sufferers may live with chronic and recurrent draining wounds. This review provides an up-to-date, evidence-based summary of HS, including clinical features, severity assessment, disease pathogenesis and current and emerging therapeutic approaches … read more

Part two of the EWMA document ‘The impact of patient health and lifestyle factors on wound healing’ focuses on two factors: physical activity and nutrition. In this paper, the pathophysiological understanding of how physical activity and nutrition either increase the risk for wounding or impact the healing process will be presented. We review current evidence for the effectiveness of interventions in improving healing outcomes and offer some recommendations for practice and further research. This part of the document should be read in conjunction with Part 11, which discussed stress, sleep, smoking, illicit drug use and alcohol misuse and described how some commonly used medications impact the healing process … read more

The outbreak of the coronavirus disease 2019 (COVID-19) led to events that significantly impaired the treatment and management of patients with chronic diabetes. Therefore, elective treatments at hospitals were cancelled and patients with chronic ailments were instructed to stay at home and minimise the time spent in public areas. The second was due to COVID-19-induced anxiety that deterred many patients from seeking care and adhering to periodic out-patient visits. In this study, we examined the short-term effects of the COVID-19 pandemic on patients with chronic diabetes who suffered from contaminated diabetic ulcers. We conducted a retrospective study with patients who had undergone amputations following diabetic ulcers during 2019-2020. The research group included diabetic amputees during the COVID-19 outbreak period ranging from March 2020 to December 2020. The control group included diabetic amputees from the corresponding period … read more

Rates of hospitalization and major amputations among racial and ethnic minority adults with diabetic foot ulcers decreased in states that adopted Medicaid expansion under the Affordable Care Act (ACA), according to researchers at the University of Arizona Health Sciences … Diabetic foot ulceration and amputation have serious health and financial implications, and the disproportionate rate at which it occurs among patients in lower socioeconomic groups is a largely recognized issue within the fields of medicine and vascular surgery … read more

HMP Global, the omnichannel leader in healthcare events and education, today announced the launch of a new program offering professionals who treat diabetic foot syndrome the opportunity to debate the most controversial topics in treatment options and gain knowledge from one another.

 

Great Debates & Updates in Diabetic Foot will be held December 2-3 in San Antonio, Texas. The unique, debate-style format will include dynamic presentations and interactive debates, while also diving into the long history of podiatry culture in San Antonio.

 

“The agenda will feature a mix of clinical updates and lively debates on provocative scientific topics impacting the field, including emerging concepts and treatment options for the diabetic foot,” said Dr. Lawrence A. Lavery, UT professor, board-certified podiatrist at UT Southwestern Medical Center, and event co-chairman. “We are excited to lead this inaugural event and provide a unique, interactive experience to the attendees, with several opportunities to network with faculty, industry, and colleagues.”

 

This year is the 50th anniversary of the podiatry residency program at the University of Texas Health Science Center in San Antonio, Lavery said, a milestone which will be celebrated at the GDU in Diabetic Foot event.

 

“There is a rich history of podiatry culture and diabetic foot research in Texas,” said Dr. Lee C. Rogers, event co-chairman and Chief of Podiatry and Associate Professor in the Department of Orthopedics at the University of Texas Health. “The Diabetic Foot Ulcer Classification System is a proven, effective, and widely used classification system for predicting hospitalization and lower extremity amputation. We look forward to discussing this, along with other important treatment tools and techniques, during the new program.”

 

GDU in Diabetic Foot is designed for the wide spectrum of medical professionals who diagnose and manage the diabetic foot, including podiatrists, wound care physicians, physical therapists, physicians-in-training, nurse practitioners, and physician assistants. The in-person meeting will allow attendees more opportunities for networking and engaging with colleagues and faculty experts.

 

“The GDU brand offers an educational experience unlike any other,” said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education. “These unique, debate-style conferences provide a comprehensive learning experience covering the latest scientific updates and controversial issues emerging in different fields. We are excited to introduce the GDU brand through important education about managing and treating the diabetic foot.”

 

GDU in Diabetic Foot offers a maximum of 9 hours of continuing education credit. Exhibit space, attendee engagement options, and branding opportunities are available to organizations interested in participating in the event.

 

For more information or to register, visit gdudiabeticfoot.com.

 

About HMP Global
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Patients with a diabetic foot ulcer who received probiotic supplementation for 12 weeks experienced faster wound healing coupled with an improved glycemic and lipid profile compared with patients assigned placebo, according to findings from a randomized controlled trial … Sima Mohseni, of the infectious diseases and tropical medicine research center at Babol University of Medical Sciences in Iran, and colleagues analyzed data from 60 adults aged 40 years to 85 years with grade 3 diabetic foot ulcer, who randomly received either probiotic supplementation (n = 30) or placebo (n = 30) daily for 12 weeks … read more

Scott Freeman, PA-C, talks post-procedure infection prevention at the current New Wave Dermatology conference.

 

Scott Freeman, PA-C, in a video for Dermatology Times®, highlighted the importance of making sure patients adhere to good wound care at the Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference being held this week in Coral Gables, Florida. Additionally, he gave pearls on infection prevention.
… watch

To Elevate Awareness Of Hyperbaric Oxygen Therapy

 

BOCA RATON, Fla., May 2, 2022 /PRNewswire/ — CūtisCare, a leader in wound care and hyperbaric management, launches its second annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy. Hyperbaric Oxygen Therapy is an effective healing option for many different chronic conditions. Still, many go years without this treatment because they are unaware of treatment indications, benefits, and the patient selection criteria of hyperbaric medicine.

 

Hyperbaric oxygen therapy (HBOT) is a proven treatment option for wounds, infections, or injuries that have not responded to standard treatment. There are currently fourteen indications for HBOT recognized by the Centers for Medicare and Medicaid Services (CMS) and other third-party payors. Hyperbaric oxygen therapy is most commonly used for the treatment of diabetic ulcers of lower extremities, radiation injury to bone or tissue, compromised grafts and flaps, and chronic refractory osteomyelitis.

 

Hyperbaric Awareness USA™ designated May Hyperbaric Awareness Month. Throughout this month (and beyond), the Hyperbaric Aware™ campaign aims to promote hyperbaric oxygen therapy benefits, which will help people prolong lives, reduce amputations, and reduce the cost of care while improving quality of life.

 

There are more than eight million people in the United States who are living with chronic wounds. Twenty-five percent of the 34 million people in the US with Diabetes will develop a foot ulcer, possibly leading to amputation. Hyperbaric oxygen therapy provides necessary oxygenation, which is critical in preventing amputation.

 

In the US, almost half of the 17 million people diagnosed with cancer will receive radiation therapy, and 10-15% will experience late effects of radiation. Many patients who undergo radiation therapy discover a hidden complication that may not come to light until years after they complete treatments. Radiation therapy can restrict oxygen in the body’s healthy tissue which is needed for the tissue to thrive. If there is a break in the integrity of the tissue, infection and non-healing wounds can occur. Hyperbaric oxygen therapy is a treatment option for patients who suffer from late radiation tissue injury stimulating the growth of new blood vessels following radiation-induced damage.

 

CūtisCare Board Chairman and CEO Jim Patrick said, “As an industry leader, we are addressing the lack of awareness of hyperbaric oxygen therapy, a critical modality for chronic wound healing and limb preservation.”

 

The Hyperbaric Aware website, in collaboration with the Undersea and Hyperbaric Medical Society (UHMS) and physician leaders, will share articles, latest research, and expert insight for physicians, patients, and the general public.

 

About CūtisCare
Headquartered in Boca Raton, Florida, CūtisCare works with hospitals, academic medical centers, hospital systems, and physicians to design customized outpatient wound care and hyperbaric oxygen (HBOT) solutions. With more than 25 years of management experience, a commitment to research, and driven by ethics and a culture of compliance, CūtisCare collaborates with its partners to reach and heal people with chronic wounds.

 

For more information, visit https://cutiscareusa.com and https://hyperbaricaware.com

 

Follow us CutisCare LLC | LinkedIn and Hyperbaric Aware|LinkedIn.

Media Contact:

Kelly Caceres
kcaceres@cutiscareusa.com
904-446-0708
SOURCE CutisCare LLC

 

This article was originally published here

Joint provider with the South Carolina Podiatric Medical Association
Up to 20 continuing education contact hours
From $299/per night, Rate guaranteed until 05/23/22 or until room block is filled
Footprints in the Sand for Assistants: The Program will offer the ASPMA Radiology Certification Exam.
… register

available for purchase

Angela Gibson, MD, PhD, FACS, Aiping Liu, PhD, Collin L Tran, BS, Sameeha E Hassan, BS

 

Chlorhexidine (CHG) is ubiquitous in surgical perioperative care. In vivo studies of CHG cytotoxicity on human skin are lacking. Given the use of CHG for daily wound cares and as a presurgical scrub, including donor site preparation, we sought to identify if CHG cytotoxicity would persist in a clinically relevant in vivo human skin xenograft model … read more

Several iodine formulations have been used for wound care for ages, but still there exist a number of controversial issues regarding their uses in the present era. Many published studies are available for both povidone iodine (PI) and cadexomer iodine (CI) with conflicting outcomes due to different preparations used and different study types. PI has a broad spectrum of activity including antiseptic properties, anti-inflammatory properties, low cytotoxicity, and good tolerability with the absence of associated resistance. CI is an immobilized iodine molecule in a hydrophilic modified-starch polymer bead with the dual property of cleansing the wound by absorbing the exudate and bactericidal effect by sustained release of iodine molecules over the infected wound. The preparations comprising PI and CI improve wound healing and minimize the bacterial infestation or contamination in various chronic wounds, burns, and ulcers. This review narrates the comparison of CI and PI for the management of wounds in the context of biofilm reduction, wound size reduction, and granulation tissue promotion … read more

Research findings from two studies demonstrate the antimicrobial effectiveness of STIMULAN® and genex®, when mixed with antibiotics

 

KEELE, England, April 12, 2022 /PRNewswire/ — Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held in Lisbon, Portugal on 23-26 April 2022. The company’s in-vitro research findings demonstrate the antimicrobial effectiveness of both STIMULAN® and genex® when mixed with antibiotics.

 

The first abstract demonstrates that STIMULAN® beads containing vancomycin and gentamicin were able to inhibit bacterial growth, when applied to tissue taken from diabetic foot infections, with zone of inhibition diameters ranging from 12-40mm.

 

The second abstract demonstrates the ability of genex® when mixed with combinations of vancomycin/gentamicin and vancomycin/tobramycin to prevent the formation of bacterial biofilms by MRSA, S. epidermidis and P. aeruginosa for up to 7 days on orthopaedic implant materials.

 

Both studies were co-authored by Julie Fletcher from the University of Exeter whom Biocomposites first funded in 2017 through the Daphne Jackson Trust, the UK’s leading organisation and independent registered charity dedicated to realising the potential of returners to research careers following a career break.

 

Dr Julie Fletcher, Research Fellow, The University of Exeter, said: “This research highlights the potential to use STIMULAN to achieve high local concentrations of antibiotic within poorly vascularised tissue to inhibit bacterial growth at a wound site, with the possibility of facilitating clearance of bacterial infection and improving wound outcomes. The genex research shows the potential to use genex as a carrier of antibiotics to prevent the formation of bacterial biofilm for up to 7 days on orthopaedic implants.”

 

Michael Harris, Chief Executive Officer of Biocomposites, added: “By presenting this new data at this important annual congress, we are pleased to further support the vital research being carried out by leading scientists. STIMULAN and genex are valuable tools for a surgeon and together help over 65,000 patients every year.”

 

STIMULAN® is the only calcium matrix antibiotic carrier approved to treat bacterial infection in surrounding soft tissue in Canada and for use in bone and soft tissue in EU, UK, and Saudi Arabia. STIMULAN® offers surgeons the flexibility to apply broad spectrum ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans – dramatically improving patient outcomes and redefining standard of care.

 

genex is a biphasic composite of exceptional purity that is specifically formulated to balance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture.

 

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

 

This article was originally published here

WoundZoom Digital Wound Management and MatrixCare provide seamless wound care communication for customers

 

STEVENS POINT, Wis., April 26, 2022 (GLOBE NEWSWIRE) — Perceptive Solutions, Inc., developer of WoundZoom Digital Wound Management, today announced its integration partnership with MatrixCare. The purpose of this partnership is to provide a seamless exchange of wound care data between WoundZoom and MatrixCare Customers’ EHR system.

 

As trusted integration partner with MatrixCare so Perceptive post-acute customers can leverage the benefits of WoundZoom while eliminating additional steps in their workflow. Data captured using WoundZoom at the bedside, such as precise wound measurements, images, and clinical assessments automatically sync to patients’ charts, creating a more efficient workflow and a complete patient record in the EHR.

 

“We are excited to add MatrixCare as a strategic EHR partner, the partnership will enable seamless and efficient data flow from our WoundZoom product platform into MatrixCare clinical charts. This enables healthcare facilities to more efficiently share valuable wound care data between both clinical and administrative team members within their EHR,” said Mark Lacerte, President of Perceptive Solutions. “Our innovative digital wound management solution enables clinicians to spend more time with patients through automated charting, wound imaging and elimination of the manual measurement process. We are excited to provide accessibility of WoundZoom to post-acute MatrixCare customers.”

 

About Perceptive Solutions

Perceptive Solutions modernizes the practice of wound care with technology-enabled systems designed to increase clinical efficiency, improve care quality, and mitigate risk. Integrating smoothly with your EHR, WoundZoom utilizes the latest AI and imaging technology to capture accurate wound images and measurements from your smart device, automatically prompt and document appropriate actions, and create a continuous, standardized clinical record across shifts, floors, and facilities. For more information, visit https://perceptivesol.com.

 

Media Contact

Karen Guzdzial
Director of Marketing
(727) 225 7944 karen.guzdzial@woundzoom.com

According to the United States (U.S.) Department of Health and Human Services, the Hispanic/Latino ethnic group includes any person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. In the U.S., states with the largest Hispanic populations are California, Texas, Florida, New York, Arizona, Illinois, New Jersey, Colorado, Georgia, New Mexico … Patient education materials in Spanish are paramount to wound care and hyperbaric services looking to offer the highest standards of clinical practice, and can help clinicians save time while engaging patients … read more

A topical gel that contains birch bark extract as the active ingredient — Filsuvez (Oleogel-S10) — has been recommended for approval for the treatment of skin wounds in patients with epidermolysis bullosa (EB) by the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use … “The benefit of Filsuvez is its ability to promote healing of EB partial thickness wounds,” the EMA said in an announcement on April 22. “It is thought to work by modulating inflammatory mediators and stimulating keratinocyte differentiation and migration, thereby promoting wound health and closure,” the statement adds … read more

a new class of molecules for treating biofilm infections

 

BATON ROUGE- Chronic skin wounds are a growing global concern amongst aging populations and patients with severe burns and underlying health conditions such as diabetes. Commonly seen in healthcare environments and long-term care facilities, patients with chronic skin wounds suffer from persistent pain and potentially life-threatening infections.

 

Effective treatments for these wounds are often challenged by a biofilm, a community of bacterial cells entrenched in a self-produced matrix of extracellular DNA, proteins, and sugar molecules. Bacterial cells in biofilms are tolerant to the body’s immune response and most commercial antibiotics that normally kill free living, or planktonic, bacterial cells.

 

The antibiotic recalcitrance of biofilm bacteria is further complicated in biofilm infections with multidrug resistant, or MDR, bacteria. Therefore, successful treatment of MDR bacterial biofilm-associated infections require alternative treatment strategies.

 

LSU Professor and William A. Pryor Chair in Chemistry Mario Rivera recently received a five-year $3.69 million National Institutes of Health, or NIH, R01 grant to develop a new strategy to kill biofilm-embedded cells and combat biofilm infections caused by MDR bacteria, Pseudomonas aeruginosa and Acinetobacter baumannii.

 

The new antibiofilm approach involves a new target that would disrupt the bacterial iron homeostasis, or the balanced state of intracellular iron, in the biofilm. Iron, an essential metal for all living organisms, is a crucial nutrient for the growth and survival of most bacterial species. Rivera’s research team aims at disrupting bacterial iron homeostasis by inhibiting a specific protein-protein interaction.

 

Bacterioferritin, or BfrB, is a spherical and hollow protein that can store thousands of iron atoms in its interior. Rivera and colleagues demonstrated that the mobilization of iron stored in BfrB is an essential process in bacterial cells, which requires BfrB to form a complex with Bfd. The scientists aim to disrupt the BfrB-Bfd protein-protein interaction.

 

They also discovered proof-of-concept small molecules that can inhibit the BfrB-Bfd complex and cause an irreversible accumulation of unusable iron in BfrB, which leads to iron deficiency, metabolic stress, and bacterial cell death in the biofilm. The proposed work supported by the new grant is directed at optimizing the proof-of-concept inhibitors of the BfrB-Bfd complex into drug lead molecules, that is, powerful inhibitors that kill bacterial cells in biofilms but also have desirable drug-like properties.

 

The funded research project involves a talented, multidisciplinary team of drug discovery collaborators from LSU and other institutions, including:

• Professor Mario Rivera (PI), Department of Chemistry, Louisiana State University
• Research Associate Professor Huili Yao (co-PI), Department of Chemistry, Louisiana State University
• LSU Chemistry postdoctoral researcher Anabel Soldano and graduate students Leo Fontenot, Nimesha Rajapaksha, Suliat Alli and Alexanndra Behm.
• Associate Professor Josephine Chandler (co-PI), Department of Molecular Biosciences, University of Kansas
• Dr. Scott Lovell (co-PI), Director of the Protein Structure Laboratory, University of Kansas
• Professor Richard Bunce (co-PI), Department of Chemistry, Oklahoma State University
• Professor Lisa Morici (co-PI), Tulane University School of Medicine
• Dr. Allen Reitz (co-PI), Fox Chase Chemical Diversity Center

 

If the proposed strategy proves successful, validation of the novel antibiotic target would lead to the development of an entirely new class of antibiotics for the treatment of biofilm-associated infections. To learn more about the Rivera research group and their work on iron homeostasis in bacteria as a potential target for antibiotic development, visit their group page.

 

Media Contact:
Gretchen Schneider
LSU Chemistry
gschne2@lsu.edu

The normal wound healing process involves a complex series of four overlapping but distinct steps. During the initial steps, platelets from the blood control bleeding by signaling the formation of a protein matrix plug; they also generate molecules that will constrict blood vessels and mobilize other types of cells to the site. These additional cells kill pathogens in the wound area and trigger wound healing and blood vessel formation. In later steps, the protein matrix, blood vessel growth and connections are even further developed, and skin and other surface cells begin to migrate to the site. Together, the skin and protein matrix form granulation tissue to repair and close the wound … read more

Porous, resorbable biomaterials can serve as temporary scaffolds that support cell infiltration, tissue formation, and remodeling of nonhealing skin wounds. Synthetic biomaterials are less expensive to manufacture than biologic dressings and can achieve a broader range of physiochemical properties, but opportunities remain to tailor these materials for ideal host immune and regenerative responses. Polyesters are a well-established class of synthetic biomaterials; however, acidic degradation products released by their hydrolysis can cause poorly controlled autocatalytic degradation. Here, we systemically explored reactive oxygen species (ROS)–degradable polythioketal (PTK) urethane (UR) foams with varied hydrophilicity for skin wound healing … read more

Stephen “Andy” Rohrer, MSN, RN, APRN, AGACNP-BC, FNP-BC, CWS

 

Seemingly at the mercy of “the C-suite,” many of us have come to loathe hearing the sound of “important shoes” walking down the hall, which means an administrator is lurking. Indeed, profitability and viability have always been elusive to this group of individuals. Historically, they have defined the value of the wound center in terms of the volume of hyperbaric oxygen therapy (HBOT) treatments but HBOT services are at a 14-year low, based on Medicare claims data. Referrals to radiology, laboratory, surgery, cardiology, vascular medicine, durable medical equipment, and infusion services are always missing on monthly reports. Many of us fairly look on with resentment as those departments benefit from the fruits of our labor. Their productivity is always on the winning side while the needs of our specialty go ignored … read more

A new study compares the regenerative potential of blood/bone marrow aspirate concentrates obtained from arterial blood, venous blood, and bone marrow aspirate. The study, conducted in rabbits, is reported in the peer-reviewed journal Tissue Engineering Part A … Blood concentrate material such as platelet-rick fibrin (PRF) is used in clinical practice to promote tissue regeneration in the fields of dentistry, orthopedic surgery, and plastic surgery. In the current study, Masako Fujioka-Kobayashi, from The Nippon Dental University, Tokyo, Japan, and colleagues, introduce a new type of solid bone marrow aspirate concentrate (sBMAC) material and show its regenerative potential in both gingival fibroblasts and osteoblasts in vitro compared with that of conventional PRF … read more

Experts from various countries will meet at the International Congress of the discipline organized by the Faculty of Medicine of the Universidad Católica del Norte.

Between April 7 and 9, the International Congress of Medicine and Hyperbaric Oxygen Therapy will be held, Coquimbo 2022. The event will be online and completely free. It will have the presence of internationally renowned exhibitors in the discipline from the United States, Spain, Argentina, Italy, Sweden, Brazil, Poland, Mexico and Chile.

Professionals from different health disciplines from all over Chile and the world can participate. To access, they only need to register in advance on the website www.hyperbariccongress2022.com

One of the novelties will be the presentation of the advances in studies on the projections of this type of treatment in patients who have suffered from Covid-19. In addition, during these days researchers will present on hyperbaric oxygen therapy as a complementary treatment for wounds and tissue regeneration and oncology, among other pathologies … read more

Windy Cole, DPM, CWSP

 

Hi, I’m Dr. Windy Cole. I am the director of Wound Care Research at Kent State University College of Pediatric Medicine. And I’m here to talk a little bit about my presentation, Energy First Harnessing the Power of Pulsed Acoustic Cellular Expression … PACE therapy, otherwise known as pulsed acoustic cellular expression is the use of biphasic high energy acoustic shockwave, very similar to lithotripsy or ESWT extracorporal shockwave therapy you might be familiar with in the field of medicine … read more

Donna Morrow, WCC DWC OMS RN, Wound Nurse Manager at Nizhoni Health

Wound care has changed a lot over the years, as a result of technological advancements and has now become an ever-expanding field in which people are certified. When I first started working in wound care, people who treated bruises in hospitals were deemed the wound experts. However, it is a precise science today; you must follow protocols and get certifications for ostomy, diabetic wounds, and even primary wound care. More nurses in the field are becoming certified to deliver better patient care, which I think is a massive transformation … Technology has revolutionized wound nursing. Before, we used to travel miles across the state to see patients, make recommendations, and build a treatment protocol. Now, with technology, nurses in the field can receive a photo of the wound to get a clear picture of the condition of the injury. Such visibility into the wound provides critical information about the measures of the injury and types of tissues affected. This can save a lot of time for nurses, enabling them to see upwards of 20 patients rather than just 2 to 3 patients per day … read more

Expert Panelists: Christi Cavaliere, MD, Venita Chandra, MD, FACS, Daniel Eiferman, MD, MBA, FACS, Jeffrey E. Janis, MD, FACS, Jarrod P. Kaufman MD, FACS, Hayato Kurihara, MD, FACS, FEBS, Martin I. Newman, MD, FACS

 

This issue I am tackling a new topic for On the Spot: wound care. This topic, which transcends all surgical specialties, is new territory for me. I’d like to thank Christi Cavaliere, MD, for helping me understand some of the current practices and debates in this field. So is wound care practice, as one panelist phrased it, “more style than science”? Is hyperbaric oxygen therapy all it’s cracked up to be? And is wound care really the “Wild Wild West” of patient care? Read on to see what some of the experts think!
… read more

Findings also confirm platform’s capabilities for wound and skin clinical trials

 

PITTSBURGH, April 18, 2022 /PRNewswire/ — Net Health, a leading provider of software and analytics for medical specialties, announced the recent publication of a study reviewing the use of artificial intelligence (AI)-enabled mobile wound care applications developed by Net Health. The study showed that these applications provide better documentation, are easy to use, engage patients, and drive improvements in wound measurement and management.

 

Conducted by Australian New South Wales (NSW) Health Service, the study looked at the performance of Net Health’s Tissue Analytics’ wound imaging and analysis platform in multiple sites, including a senior care ward, colorectal ward, an outpatient dermatology clinic, and primary care physicians’ offices.

 

In addition to highlighting the platform’s value in clinical settings, the findings provide helpful insights for researchers looking to conduct decentralized and hybrid clinical trials involving wounds, skin lesions, and visible skin conditions in a post-pandemic world.

 

Statistically Significant Findings
The study was published in the International Wound Journal. The e-clinical platform was tested on 124 patients with 184 wounds compared with the standard care group, consisting of 166 patients with 243 wounds. Results showed several statistically significant outcomes related to use of the platform, including the completeness of documentation based on the number of dressing changes compared to standard care, pain, size, exudate, and odor (p < 0.001). These findings demonstrate the positive impact of the platform in terms of usability, patient adherence, and the photographic evidence of clinical endpoints.

 

As described in the publication, ten of the 13 participating physicians and nurses responded to a survey, and strongly agreed that the platform had value, and provided benefits to communication. The patients who were interviewed unanimously commented that the platform provided benefits to their wound healing and communication with clinicians.

 

Highlights Value for Clinical Research
Besides showcasing the value of mobile wound analysis in clinical settings, the findings will fuel interest in the Tissue Analytics platform for wound and skin care clinical research. Findings from the study that relate to clinical trials include the ability of the mobile wound analysis platform to: 1) empower patients to take more active roles in their care; 2) increase accuracy of wound measurements; and 3) ensure greater consistency in care and participant satisfaction.

 

Study results also suggest the value of the platform to retain study participants. Per interviews, patient-participants said they were “strongly” satisfied by the telehealth capability of the platform. Moreover, the study’s authors noted that using the app saved patients time and cost, especially for travel, a key factor in encouraging participants to remain in a study.

 

“We’re very excited by the findings in this study,” said Keith Tode, Vice President of Clinical Research for Tissue Analytics. “Study sponsors are looking for tools that are simple to use, engage patients, allow for virtual wound care visits and consultations, and provide real-time and real-world insights into the participant experience. This study shows that mobile wound platforms can offer the features today’s clinicians and researchers want and need. Looking ahead, we see many benefits to this approach for clinical trials for wound care, dermatology, endocrinology and other skin conditions.”

 

About Net Health
Net Health’s mission is to harness data for human health. Net Health solutions are trusted in over 23,000 facilities across the continuum of care. Our EHR software enables caregivers and their organizations to engage effectively with patients, streamline documentation, staff efficiently, secure maximum appropriate reimbursement and maintain regulatory compliance. Our unique approach to analytics seamlessly presents insights in clinical and operational workflows to improve care and business performance. Net Health is a portfolio company of The Carlyle Group, Level Equity and Silversmith Capital Partners. www.nethealth.com.

 

SOURCE Net Health Systems, Inc.

 

This article was originally published here
 

4/27 – 4/30

MedStar Georgetown University Hospital’s Diabetic Limb Salvage Conference is providing compelling content for the 2022 conference in a virtual format. This annual conference focuses on a multidisciplinary team approach that provides each member of the healthcare team with the education and resources needed to heal wounds and prevent amputations. It features a prominent international faculty that promotes the importance of a multispecialty approach in limb salvage. The course is designed for healthcare practitioners of all specialties and promotes an evidence based approach with emphasis on take-home points, techniques, and functional outcomes. The meeting format will include didactic lectures and specialty symposia for the purpose of providing an interactive learning experience. Here’s what you can look forward … read more
Brochure

To describe results of a study evaluating a Projected Augmented Reality (P-AR) system for its potential to enhance nursing education about pressure injuries … he sample comprised nursing students and faculty at a school of nursing in a large, Midwestern public university. A total of 32 participants, which included 27 students (30% BSN, 44% MN, and 26% DNP students; 81% female) and 5 faculty members (80% female) participated … read more

As you know, managing patients with chronic ulcers requires physicians and other qualified healthcare professionals (QHPs) with specialized knowledge and expertise. Unfortunately, this country has a shortage of chronic ulcer management professionals. Therefore, many physicians/QHPs who do not have the required knowledge do their best to manage chronic ulcers by trial and error. Many of these physicians/QHPs wish they could consult with physicians/QHPs who have chronic ulcer management expertise. In addition, even the physicians/QHPs who have such expertise are often stumped on difficult cases and wish they could consult with other colleagues who may have experienced similar cases … read more

Nanodroplets for the Treatment of Infected Chronic Wounds

 

Chronic wounds (CWs) – nonhealing breaks of the skin epithelial continuity longer than 42 days – are usually characterised by persistent hypoxia, intensified inflammation, and altered balances between matrix metallo-proteinases (MMPs) and their endogenous inhibitors; moreover, microbial infection frequently complicates CW status. CWs affect a large fraction of the population worldwide – especially the elderly – jeopardising the physical health and the economic system of industrialised countries. It is estimated that 1% to 2% of the population will experience a CW during their lifetime. For this reason, it is important to find more effective treatments to heal CWs and to prevent serious complications such as infections, which can lead to amputation, to improve health of patients … read more

The paper I have chosen for this commentary is not a clinical research paper, but hopefully one that will stimulate everyone whether from a clinical, educational, managerial or industry-based workplaces. It is from China, reviewing the global trends for research activity and hotspots in diabetic foot ulceration (DFU). It examined the DFU research activity using the Science Citation Index Expanded (SCI-expanded) of Web of Science Core Collection (WoSCC) using key words, such as ‘diabetic foot ulcer’ or ‘diabetic foot wound’. This database was used as it was deemed to cover most of the high impact and quality international scientific journals. The information of all identified publications included title, year of publication, author, affiliations, nationalities, journal, abstract and keywords. A total of 5,869 publications on DFUs … read more

Based on the analysis of electronic health records from 480 clinics, we found that better care quality and continuity are associated with better-than-expected wound healing performance … Chronic wounds, defined as wounds that “fail to proceed through the normal phases of wound healing in an orderly and timely manner,”1 affect 6.5 million Americans and result in $50 billion in annual Medicare expenditure.2-4 Despite growing prevalence and economic burden in the aging US population, chronic wound care remains an area with inconsistent adherence to evidence-based recommendations and variable quality of care.5 For example, despite evidence-based recommendations for compression therapy for venous ulcers and total contact casting (TCC) for offloading of pressure for diabetic foot ulcers, a previous study involving 2404 patients from 18 hospital-based … read more

OAKVILLE, ONTARIO (PRWEB) APRIL 12, 2022

 

HEALTH ESPRESSO INC. a company focused on introducing a collaborative, Inter-professional virtual health record in community within the Allied Health and home care sectors that is connected to primary care, hospital and other digital health assets, today announced the recent appointment of Dr. Robyn Evans as Health Espresso’s Advisor, Skin Health and Wound Care.

 

Rick Menassa, CEO of Health Espresso commented, “We are very pleased to have Dr. Evans join us as the Company’s Advisor, Skin Health and Wound Care. She brings Health Espresso over 13 years of wound care education and research. Her extensive in-field experience as a primary care physician, coupled with her proven ability to lead within the ever evolving, rapid paced digital health environment, will add tremendous navigational support to Health Espresso’s own growth strategies as it engages with patients and front line organizations providing wound care services.”

 

Dr. Evans is advising Health Espresso’s development teams on the AI powered wound imaging tool on its mobile app. for images capture at point-of-care, integration into Health Espresso’s patient’s Electronic Health Record (EHR) on its secure, in-cloud web portal for real-time inter-professional virtual collaboration.

 

Dr. Evans valuable input and guidance is leading development of Health Espresso’s next stage to interpret wound characteristics from captured images using Health Espresso’s proprietary AI technology to direct management.

 

Dr. Robyn Evans is actively involved in clinical evaluation and management of patients with complex wounds as the Director of the Wound Healing Clinic at Women’s College Hospital. Over the past 13 years, she has developed an interest in wound care education and research. She is medical lead for Wounds Canada as well as serving on the Board of Wounds Canada. She is a lecturer at University of Toronto and part of the International Interprofessional Wound Course through University of Toronto.

 

Dr. Evans has also worked full time as a community family physician since 1992.

 

Dr. Robyn Evans attended University of Toronto Medical School. She completed her family medicine residency at University of Toronto with further training in Wound care. Prior to this she did a Bachelor of Science as well as graduate studies in Biochemistry.

 

“Complex wounds need to be acutely characterized to optimize management and improve patient outcomes” says Dr. Evans.

 

ABOUT HEALTH ESPRESSO
Inspired by front-line experience in home and community care, Health Espresso chronicles the entire patient journey. Starting with a digital patient profile and digital care plan, Health Espresso empowers health organizations to automate intake, triage and update patient records and follow through with post-discharge real-time remote patient monitoring for better health outcomes. Health Espresso provides a collaborative, patient-centered platform for Allied Health professionals, Primary Physicians and Hospitals for a ‘one patient, one care plan’ approach to care, reducing service overlaps and gaps.

 

Its secure, connected platform integrates with EMRs and government data assets for an all-encompassing view of patient records. Health Espresso’s mobile app complements its in-cloud web portal to empower physicians with real-time patient information and virtual care capability for time-sensitive decisions at the point of care, anywhere in the world. For more information, visit https://healthespresso.com

A scientific team of scientists from NUST MISIS and Institute of Cytology and Genetics of SB RAS managed to create innovative bandages based on organic polymers and silver nanoparticles, which stimulate the healing of diabetic ulcers and chronic wounds. The results of the work have been published in Pharmaceutics … Type 2 diabetes mellitus is characterized by a high level of blood glucose, which worsens the work of white blood cells. They cannot function normally, and as a result, the body becomes especially vulnerable to infections. In addition, diabetes affects blood circulation, hindering the delivery of nutrients … read more

Health Espresso, Canada’s upcoming leader in community EHR, partners with best in class, Wounds Canada, to provide an AI powered, digital solution that’s aligned with the government’s target of delivering better, more connected care and improving health equity for patients, especially those in remote communities. The partnership brings Wounds Canada’s best practices, resources and training to front-line practitioners at the point of care coupled with the ability for remote patient monitoring for better outcomes.

 

 

OAKVILLE, ONTARIO (PRWEB) APRIL 13, 2022

When Linda Moss’ father was transferred to a second hospital for rehabilitation following a brain injury neurosurgery, her family only received information about the primary reason for his hospitalization: his neurological progress. Linda Moss and her family didn’t know that their father was suffering from a pressure injury that would eventually cause osteomyelitis. It was only when their father was denied a second surgery due to complications from the pressure injury that the severity of the wound was discovered.

 

Unfortunately, this gap in communication between health-care providers, specialists and patients is far too common in the Canadian health-care system. The complete picture of patients is seldom shared, especially when they are complex or receive care from multiple partners. This leads to a lack of timely wound care and ultimately irreversible complications that can result in amputations or even death in the case of Linda Moss’ father.

 

“Care teams and caregivers are essential together, and the first step in any prevention or further complications with wounds is a communicated Care Plan,” says Linda Moss.

 

A new partnership between national organization Wounds Canada and Medtech company Health Espresso is changing this. This partnership enables front-line clinicians, patients, policymakers, and researchers to digitize a patient’s journey and connect members of allied health teams at the right time to decrease acute and hard-to-heal wounds, reduce hospitalizations and improve patient outcomes. Leveraging this technology will also enable Wounds Canada to establish a Canadian national registry that can inform further research in wound care and provide quick and easy access to Wounds Canada’s validated tools and resources for immediate bedside action by clinicians and help support wound management by patients, especially those living in outlying communities.

 

“Wounds are a serious health complication that impacts the quality of life for patients while having significant economic implications on our health-care system, and the situation has only worsened under the strain of COVID-19. In many cases, hard-to-heal chronic wounds can be avoided or, if detected in the early stages, managed effectively — but we need evidence-based solutions to help us provide the safe, equitable and timely care that patients deserve in home care and across all health-care settings,” says Mariam Botros, CEO of Wounds Canada. “That’s why Wounds Canada is excited to partner with Health Espresso to offer a skin and wound care mobile app that benefits not only patients but also clinicians, researchers and policymakers. With the launch of this digital solution, we’ll be able to improve patient care, reduce hospitalizations and lower spending on wound care while also increasing the skills and knowledge of front-line clinicians and establishing a Canadian national registry to inform further research.”

 

“As a registered nurse and private wound care consultant in rural southwestern Ontario, providing safe, timely, equitable access to interprofessional, evidence-informed care to people living with wounds can be challenging,” adds Crystal McCallum, Director of Education with Wounds Canada. “The skin and wound care mobile app that Health Espresso is developing in collaboration with Wounds Canada will address these challenges and will prove to reduce the burden of wounds and enhance the experience and outcomes of people living with wounds while enabling better use of health-care resources.”

 

Certified by the Ontario Telehealth Network (OTN) and powered by artificial intelligence, Health Espresso’s easy-to-use mobile and web-based integrative digital solution offers a connected, collaborative approach to wound care. It provides a complete digital blueprint of a patient’s overall health and history, real-time vitals data, recorded notes from hospital visits, administered medication and more for timely, well-informed decision making. Unlike many standalone solutions, Health Espresso’s unique collaborative approach allows for a broader view of the patient’s journey with access to patient records, high-quality wound imaging and analysis tools to track healing progression and understand why a wound may not be healing correctly. It also includes built-in messaging and video tools that enable physicians, wound specialists and patients — especially those in remote or Indigenous communities — to engage in live communication within a secure environment.

 

“Health Espresso’s digital solution is aligned with the government’s target of delivering better, more connected care and improving health equity for patients, especially those in remote communities,” says Founder of Health Espresso Rick Menassa. “To optimize the healing of wounds, care needs to be timely, and a structured, collaborative approach to assessment, treatment, documentation and communication based on best practices is critical for providing patients with the best possible outcomes. We are pleased to partner with Wounds Canada to offer our technology and bring their best practices, resources and training to front-line practitioners at the point of care.”

 

ABOUT HEALTH ESPRESSO
Inspired by front-line experience in home and community care, Health Espresso was created to chronicle the entire patient journey. Starting with a digital patient profile and digital care plan, Health Espresso empowers health organizations to automate intake, triage and update patient records and follow through with post-discharge remote patient monitoring for better health outcomes. Health Espresso provides a collaborative, patient-centred platform for Allied Health professionals, Primary Physicians and Hospitals for a ‘one patient, one care plan’ approach to care, reducing service overlaps and gaps. Its secure, connected platform integrates with EMRs and government data assets for an all-encompassing view of patient records. Health Espresso’s mobile app complements its in-cloud web portal to empower physicians with real-time patient information and virtual care capability for time-sensitive decisions at the point of care, anywhere in the world. For more information, visit https://www.healthespresso.com

 

ABOUT WOUNDS CANADA
Established in 1995, Wounds Canada is a charitable organization dedicated to advancing wound prevention and management for all people in Canada. They advocate for a population health approach that promotes best practices to support persons at risk of or living with wounds, health decision-makers and front-line clinicians. They develop and provide educational programs and resources and support research to advance this holistic, risk-based approach further. Wounds Canada fosters relationships with interested individuals and organizations to expand and sustain a robust wound community in Canada with mutually beneficial global connections. Their goal is to reduce the prevalence and incidence of wounds of all types and the negative consequences they bring—including patient suffering and wasted health-care dollars. To learn more, visit http://www.woundscanada.ca.

 

This article was originally published here

in Diabetic Foot Ulcer Rats via Activating PI3K/AKT Pathway and hTERT

 

Diabetes is a widespread metabolic problem in modern society. Due to long-term hyperglycemia, diabetes can cause damage to multiple systems, such as the eyes, kidneys, nerves, blood vessels, etc.1 As one of the serious complications of diabetes, diabetic foot is a chronic progressive disease caused by vascular occlusive disease, which can lead to complications.2 Once foot ulcers occur, the extremities of diabetic patients are very likely to be infected with invasive infection, leading to an increased risk of amputation.3 With the annual increase in the number of diabetic patients in the world, the incidence of diabetic foot ulcer (DFU) is also increasing, which has a great impact on family, society, and economic development. There is an urgent need to develop more effective detection and treatment methods for DFU … read more

David G. Armstrong, DPM, MD, PhD

 

The authors performed a qualitative study via interviews to investigate how patients perceive and understand their foot issues over a period of about one year. A total of 15 subjects participated, and the researchers found important data in two primary areas: how patients perceive foot ulceration and how patients perceive relevant timing with respect to foot ulceration. This included limited understanding of foot ulceration, close observation of foot problems and barriers to ulcer perception, including timing of when perception of the seriousness of the foot ulcer changed. The authors concluded that there is significant potential for education to positively impact these challenges … read more

Healogics kicked off April with its chronic foot health awareness efforts in collaboration with National Foot Health Awareness Month. Its goal: To educate the public on the importance of foot health to prevent wounds and the need for regular foot exams to detect non-healing wounds. “With the increased incidence of diabetes, foot ulcers and even amputations, it is important for those living with chronic wounds, as well as those who are at risk, to have access to information on wound healing,” said David Bassin, Healogics CEO “Throughout April, we seek to educate our communities and health care providers in an effort to improve access to wound care for all that need it.” The efforts are also part of Healogics’ 2022 Healing Can’t Wait program. The company served more than 330,000 patients last year through a network of … read more

Based on the analysis of electronic health records from 480 clinics, we found that better care quality and continuity are associated with better-than-expected wound healing performance

Objectives: To evaluate the association between clinics’ wound healing performance and clinic-level measures of care continuity, clinical quality, and sociodemographic characteristics of the population in their catchment areas.

Study Design: In this cross-sectional analysis, we analyzed electronic health records for 180,336 chronic wounds from 480 wound care clinics during the 2018 calendar year.

Methods: We measured healing performance using a clinic’s observed to expected (O/E) ratio, which is based on the rate at which chronic wounds were predicted to heal within 12 weeks given its case mix and the actual healing rate. We compared the top and bottom quintiles, in terms of the O/E ratio, of clinics. Multivariable regression was used to estimate the effect of the clinic-level measures on the O/E ratio.
… read more

New therapeutic approaches have emerged for preventing diabetic foot ulcers and promoting their healing. Endocrinologist and diabetes specialist Olivier Bourron, MD, of the Pitié-Salpêtrière Hospital in Paris, described these approaches at the 48th annual congress of the Francophone Diabetes Society … Unlike macroangiopathic complications (such as ischemic heart disease and stroke) and renal complications, foot ulcers are a diabetic complication for which there has been very little therapeutic progress over the past 20 years … read more

As technology improves and patients with more complicated problems are living longer, treating wounds in these patients is becoming more challenging, not because of the wounds specifically but because of the comorbidities and associated treatments. Our center regularly sees patients with a wound or ulcer who are also undergoing immunosuppression therapy. Patients with pulmonary disease, inflammatory diseases such as rheumatoid arthritis, skin diseases, and others take medication that influences the immune system. The more challenging patient population involves those who have received a transplant. In our practice in Alabama, there are many patients who have had kidney transplants … read more

Charleen Singh, PhD, MBA, FNP-BC, CWOCN, RN

 

This presentation will explore how to provide wound care in diverse patient populations. As global migration, whether voluntary or forced, increases, wound care practitioners must develop clinical skills that take into account the needs of diverse populations. Diversity can be thought of as what makes us different and can include factors such as age, ethnicity, and socioeconomic status, among others. However, let’s consider what connects us and how we can use that connection to appropriately care for populations that are diverse in age, ethnicity, socioeconomic status, and overall health … read more

Our educational sessions promote the best practices in skin health and wound healing.

It has been estimated that the cost of managing wounds and associated co morbidities in the NHS, is £5.3 billion a year. Approximately 2.2 million adults will suffer with a wound over a year, and largely it is nurses who care for these wounds … Wound assessment is a vital process to help ensure patients are receiving the most appropriate management plan for them. Understanding the stages of the normal wound healing process will arm health and social care practitioners with the confidence to recognise when something is not right. This session will provide the delegates with the fundamental knowledge to undertake a wound assessment, formulate a management plan and have a working knowledge of the most common dressing types used in clinical practice … read more

The world has now completed 2 years of living with COVID-19. In developing nations, especially in Africa, limited vaccine availability has led to high case rates and the emergence of new variants, some of which are more virulent or contagious than wild-type SARS-CoV-2. With the Omicron variant, the pandemic is now transitioning to an epidemic because of widespread natural virus immunity from a less-virulent infection. We may soon have a combined RNA vaccine for annual single immunization for both the influenza virus and COVID-19 … read more

The most effective wound care is patient-centered and individualized. Consideration must be made for unique population characteristics during an inpatient stay to decrease the risk of hospital readmission or further wound complications. Variations in wound care needs may exist among patients based on their ethnicity, age, socioeconomic status (SES), and comorbidities. Early identification of these characteristics and interventions to combat disparities should be considered … read more

Events include an Innovation Theater presentation that features the science and clinical results supporting Matrion®— the first full-thickness, decellularized placental membrane — and Dermacell AWM® acellular dermal matrix

 

PHOENIX, April 7, 2022 /PRNewswire/ — LifeNet Health, the world leader in allograft biologics, is showcasing its unique allograft solutions for wounds at the 2022 Symposium on Advanced Wound Care (SAWC) Spring meeting April 7-9 in Phoenix.

 

Its featured biologic portfolio includes:

Matrion®, the first full-thickness, decellularized placental membrane for wounds, and
Dermacell AWM®, the only acellular dermal matrix clinically proven to help resolve wounds in as little as one application1.
“These solutions take wound care to the next level by helping address long-standing clinical challenges,” said Mike Falcon, Vice President of Advanced Wound Management Sales. “Thanks to LifeNet Health’s unique technologies, we are bringing clinicians the most advanced allograft biologics available to facilitate healing in their patients.”

 

Innovation Theater Breakfast Presentation
Clinicians Hayway Chiu, DPM, FACFAS, and Zakee Shabazz, DPM, FACFAS will lead an SAWC-hosted Innovation Theatre session to share their experience with Matrion and Dermacell AWM. The analysis will cover the science behind these two best-in-class therapies as well as clinical results that show how they support positive patient outcomes, using real-world case studies.

 

The session, which begins at 7:30 a.m. MST Friday, April 8, will be moderated by Valerie Marmolejo, DPM.

 

Industry-Leading Solutions
Matrion is the only biologic of its kind to fully maintain the natural thickness and structure of the placental membrane. It includes the complete trophoblast layer, which is up to four times thicker than either the amniotic or chorionic membranes2. This allows Matrion to retain up to 50 percent more native growth factors than traditional placental membranes.3 Its natural thickness also means Matrion is less likely to adhere to itself or roll up during application.4

 

Dermacell AWM is backed by more than 30 publications that demonstrate its exceptional clinical performance and ease of use. It is proven to provide complete resolution of even complex wounds, with exposed bone and tendon, in as little as one application.1

 

Both Matrion and Dermacell AWM are decellularized with LifeNet Health’s patented Matracell® technology to remove donor cells and create a biohospitable scaffold for cellular infiltration and re-vascularization.

 

About LifeNet Health
LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world’s most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.

 

1. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.
2. Verbruggen SW, Oyen ML, Phillips AT, Nowlan NC. Function and failure of the fetal membrane: Modelling the mechanics of the chorion and amnion. PLoS One. 2017;12(3):e0171588.
3. LifeNet Health. TR-004-2020 Characterization of the Amnion, Chorion, and Trophoblast Layers of Decellularized and Freeze-Dried Placental membrane. 2020.
4. LifeNet Health. ES-20-057, Placental Membrane for Wound: Design Validation. Data on File. 2020.
   SOURCE LifeNet Health

 

This article was originally published here

Due to Non-Healing Wounds During Limb Loss Awareness Month

 

SIERRA MADRE, Calif., April 7, 2022 /PRNewswire/ — Wound Care Advantage (WCA), the leading provider of support services for wound care programs, is proud to release the first digital network platform for wound centers, LUVO. Available now, LUVO supports wound centers by offering a suite of digital tools designed to streamline and simplify day to day operations, allowing program leaders to get more done in less time.

 

 
WCA was founded 20 years ago with a singular goal: to eliminate amputations caused by non-healing wounds within our lifetime. To that end, WCA is dedicated to building a national network of profitable and effective wound centers that can treat non-healing wounds in their community before amputation is the only option. LUVO makes this possible. The platform modernizes referral management, offers intelligent reporting that lets leaders know where their center stands, and offers a direct line to WCA experts for chart reviews, audit assistance, and general guidance. A full list of tools can be found at www.thewca.com/expertise/technology

 

“Wounds lead to amputations, amputations lead to death. LUVO was created to break this cycle,” says CEO Mike Comer. “LUVO can strengthen any wound center, works with any EMR system a hospital may use, and is the most cost-effective option for wound center operations. It ensures wound programs operate efficiently and effectively while keeping their doors open for the next generation of wound care patients.”

 

April is Limb Loss and Limb Difference Awareness Month, a time to raise awareness about this issue and remember the millions of people living with limb loss. Of the estimated 150,000 lower limb amputations performed in the U.S. each year, approximately 82 percent stem from a diabetic foot ulcer. Patients undergoing these procedures have a three-year mortality risk of 71 percent. By incorporating LUVO into wound centers, they can run more effective and profitable healing programs, without bringing in an outside management company.

 

“Having LUVO in our centers means more gets done everyday with less frustration. It’s become the heart of our program,” says Mary Mary Brightwell Tuttle, Program Director at Placentia-Linda Hospital Center for Wound Care. “Our staff and clinicians can focus on patients because LUVO handles so much of our busy work, tracks metrics across our program, and catches errors before we make them.”

 

The LUVO platform powers the WCA Network of independent wound centers across the country, allowing every hospital to take advantage of the cost effective benefits of joining a powerful cohort of wound centers dedicated to eliminating wound related amputations.

 

“Having subject matter experts available to answer questions, review documentation, or help with reimbursement whenever we need them has proven to be indispensable,” Tuttle says.

 

Discover how you can unlock the full potential of your center with LUVO. Start a conversation today by calling 888-484-3922 or emailing info@thewca.com.

 

About Wound Care Advantage
Founded in 2002, Wound Care Advantage (WCA) has been a leader in reimagining how wound care programs operate across the United States. To learn more, visit: www.thewca.com/about

 

SOURCE Wound Care Advantage

This article was originally published here

Diabetic foot ulcer (DFU) is one of the most serious complications of diabetes.1 Epidemiological investigation found that the global prevalence of DFU is 6.3%, and what is more troublesome is that DFU also has a high recurrence rate.3 Cohort studies have shown that DFU have a high mortality rate in both developed and developing countries, with a 5-year mortality rate of up to 42%. With high morbidity and mortality, DFU has been the main cause of nontraumatic lower-limb amputations. We have developed a model for predicting the risk of early DFU, which may potentially guide early intervention. Hyperglycemia impair immune cells activity in eliminating pathogens, while severe infection can cause stress hyperglycemia. The interaction of the two ways has resulted in a rapid development of diabetic foot infection (DFI) and sometimes a necrotizing abscess can be developed in just 6 days. Early empiric antibiotic treatment is necessary due to the long culture time of microorganisms and the lack of basic microbiology laboratories. But Multidrug-resistant organisms (MDROs) infection is easy to make antibiotic treatment failure, increasing the difficulty of diabetic foot treatment … read more

Kerecis selection for the iSupply program announced at the Symposium for Advanced Wound Care

Kerecis, the company pioneering the use of fish skin and fatty acids in cellular therapy, tissue regeneration and protection, announced today that the company‘s products have been added to the Healogics iSupply program. This makes Kerecis medical-fish-skin products available to Healogics Wound Care Centers®, expanding the options to treat chronic, non-healing wounds. The announcement was made at the Symposium for Advanced Wound Care (SAWC) Spring meeting. Kerecis is pioneering the use of fish skin and fatty acids for tissue regeneration and protection globally. Healogics is the leading provider of world-class wound care services in the United States … read more

the Future of Wound Care Management

 

BOSTON, April 6, 2022 /PRNewswire/ — Healthy.io, the global leader in transforming the smartphone camera into a medical device, and Innovive Health, a data-driven home health care agency serving complex behavioral health patients, today announced a new partnership through which up to 700 Innovive nurses will use Healthy.io’s digital wound management service, Minuteful for Wound to enhance and extend patient care. The partnership illustrates how clinicians can use smartphone technology to track and treat chronic wounds like diabetic ulcers while enabling them to do their job more efficiently.

 

Innovive Health aims to revolutionize the treatment and care of chronic wounds in its vulnerable patient population by combining the company’s patient-centered, data-driven approach to home health care with Healthy.io’s smartphone-based service designed to enable healthcare providers to perform consistent and accurate wound measurement. Innovive Health’s ultimate goal is to improve continuity of care and allow clinicians to focus more of their time on patient care.

 

“We are thrilled about this partnership with Innovive Health,” said Healthy.io US General Manager Paula LeClair. “Innovive provides care to some of society’s most vulnerable and underserved communities, which aligns perfectly with Healthy.io’s mission. Together, we can change the way nurses use technology to monitor patients quickly and efficiently. COVID-19 brought to light the need for technology like our wound care product, which is key to helping nurses save precious time monitoring patients.”

 

“We’ve seen the ways Healthy.io has successfully changed wound care management and we are excited to partner with them to help our nurses accurately and consistently monitor chronic wounds. Any nurse can use this technology, which will result in more equitable patient care,” said Innovive Health’s CEO Joseph McDonough. “Innovive Health’s commitment to excellence coupled with Healthy.io’s vision-based medical technology can improve patient care for those suffering from particularly complex chronic wounds.”

 

Through this partnership, Innovive Health’s nurses use a smartphone to scan a wound before uploading the scan into a portal that allows them to assess whether the healing is proceeding properly. The AI-powered computer vision system analyzes wounds with optimal accuracy, automatically calibrating images for scale, lighting, dimensions, and 3D structure.

 

Healthy.io is confident this partnership will make it easier for nurses to manage wound care. Nurses using the Healthy.io wound management tool reported 85% faster documentation compared to standard methods and 67% reduction in their time for follow-up visits.

 

About Healthy.io

 

Healthy.io transforms the smartphone camera into a medical device to deliver healthcare at the speed of life. The company’s at-home urinalysis and digitized wound care services enable providers and healthcare systems to close gaps in access and care while increasing patient satisfaction. Healthy.io is a global leader in digital health and is a recipient of the CNBC 2020 Disruptor 50 Award, Fast Company’s World’s Most Innovative Companies 2020 Award, and the Financial Times 2020 Boldness in Business Award. The company is based in Tel Aviv and has offices in Boston and London.

 

About Innovive Health

 

As one of the leading home care health agencies in Massachusetts, Innovive Health has been delivering strong clinical outcomes for more than two decades and is transforming healthcare through an innovative model of patient-centered, data driven, full-service home care. Innovive Health provides high quality nursing, therapy and services to some of the region’s most vulnerable and underserved populations in the safety and comfort of their homes and communities. For more information, visit https://innovivehealth.com.

 

Media contact:

Kate Lucadamo
Vice President at Marathon Strategies
Kate@marathonstrategies.com

 

For Innovive Health
Travis Small
tsmall@sloweymcmcanus.com

SOURCE Healthy.io; Innovive Health

 

This article was originally published here

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) — Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, NuShield®, Novachor™ and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022 in Phoenix, Arizona.

“As a leading sponsor of this year’s conference, we are excited to share new research on our innovative product portfolio and hear from other thought leaders about advances in wound care,” said Katie Mowry, Assistant Vice President, Research and Development for Organogenesis … read more

Isn’t it a boon that all living organisms possess the ability to heal their injuries? The wound healing is faster when the normal physiology of the wound healing is maintained. Our understanding of wound healing has undergone dramatic changes in the recent past. Almost all materials and methods available on earth have been used and tested to facilitate the process of wound healing. The mental agony and the disability suffered by patients with chronic ulcers have led to the reappraisal of the basic components of the wound healing process and how they are influenced by biological, mechanical, and physical forces … The Department of General Surgery in our Government Chengalpattu Medical College and Hospital, Chengalpattu, Tamil Nadu, India, admits and treats a large volume of patients with wounds and ulcers. Here many materials are being used regularly for dressing to make wound healing faster. Vacuum dressings were also done on many patients, and promising results were observed. This kindled our interest in conducting this prospective study and comparing wound healing with vacuum dressing versus normal saline dressing … read more

Patients with dystrophic epidermolysis bullosa had positive phase 3 results with Vyjuvek treatment, Krystal Biotech announced in a press release … Vyjuvek (investigational beremagene geperpavec) is a noninvasive, topical, redosable gene therapy … The randomized, double-blind, intra-patient, placebo-controlled phase 3 GEM-3 trial enrolled 31 patients with dystrophic epidermolysis bullosa … read more

The Wound Pros (https://thewoundpros.com/) has announced Dr. Swati Hans as its new Vice President of Business Development. The Wound Pros is the nation’s largest wound care management company specializing in the treatment and management of chronic non-healing wounds in long-term care facilities. It partners with skilled nursing facilities, hospice agencies, and home healthcare companies to offer advanced wound care dressings and biologics (skin substitutes) to heal acute and chronic non-healing wounds … Dr. Hans joined The Wound Pros in January 2022 as VP of Business Development specifically to manage the growth of the skilled nursing facility sector. In her new role, she will work closely with The Wound Pros Senior Vice President of Sales and Marketing, Daniel Yeager … read more

Alisha Oropallo, MD, FACS, FSVS, FAPWCA, FABWMS Adrian Chen, BS

The outbreak of the COVID-19 pandemic has accelerated the implementation of telemedicine in hospital and private settings. Telemedicine is the usage of a remote electronic interface to permit two-way, interactive communication between a patient and physician to discuss patient concerns and history.­ The widespread adoption of this technology has enabled flexible interaction with the patient regardless of time and location, and more importantly to limit unnecessary exposure, particularly for high-risk individuals … read more

The Alliance submitted a follow-on letter to CMS and its National Correct Coding Initiative (NCCI) Contractor continuing to urge consideration of our requests for edits. While through our advocacy efforts we successfully achieved an update to the NCCI manual in 2021 allowing for debridement and compression to be provided on the same day, the correlating changes to the edits table were not made at that time. The Alliance has again advocated for this change, emphasizing that “making this change without deleting the corresponding procedure-to-procedure edits does not sufficiently address the problem of Medicare beneficiaries being denied access to these important, limb and life-saving services … read more

of 80% Methanol Leaf Extract of Brucea antidysenterica J.F. Mill (Simaroubaceae)

 

A wound is defined as damage or disruption to the normal anatomical structure and function of a living tissue. This ranges from a simple disruption in the epithelial integrity of the skin to deeper subcutaneous tissue involvement and also damage to other structures, like muscle and bone.2 Wounds can arise from physical, chemical, thermal, microbial, or immunological damage to a tissue or can be the result of a disease process like diabetes mellitus.

 

Wounds have considerable humanistic and economic burdens, both at individual and societal levels. A wound deters individual quality of life and productivity; and is associated with major economic burdens on the health care system. The current situation worldwide estimate of people with chronic wounds rises to 6 million each year. In developed countries, 1–2% of individuals in a population acquire a chronic wound during their lifetime.5 Globally, the economic burden of chronic wound is estimated to be nearly 2–4% of the health budgets.

 

Wound healing is the complex and dynamic process of restoring the structure and function of damaged tissues. It follows coordinated interactions between diverse immunological and biological systems. The interaction involves a cascade of ordered and precisely regulated steps and events, which are divided into four overlapping but distinct phases, ie, the hemostasis/coagulation phase, the inflammation phase, the proliferation phase, and the remodelling phase … read more

The West Virginia Supreme Court ruled that a diabetic worker was entitled to expand the scope of his claim for a foot ulcer to include additional conditions after an infection migrated into the bones.

Case: Constellium Rolled Products v. Leonard, No. 20-0812, 03/23/2022, published.

Facts: William Leonard worked for Constellium Rolled Products as a casting operator. He developed a diabetic ulcer and left foot cellulitis in the course of his employment.

A treatment note by Activate Healthcare, dated March 31, 2017, indicated Leonard had reported a chronic problem with left foot blisters … article available for purchase

Lakewood-Amedex’s Second Clinical Trial for DFU Using New Nu-3 Gel Formulation Top Line Results Expected in December 2022

 

SARASOTA, Fla., April 5, 2022 /PRNewswire/ — Lakewood-Amedex, Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins®, announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU). More than 34 million adults in the United States have diabetes mellitus (Source: CDC), and complications of DFU are responsible for about 85% of the non-traumatic lower extremity amputations per year, creating a tremendous morbidity, mortality, and financial burden on the healthcare system.

 

The Phase 2 study is a randomized, multi-center, double-blind, placebo-controlled, dose-escalating study to evaluate the safety and tolerability of topically applied Bisphosphocin Nu-3 gel on Type I or II diabetes mellitus patients with chronic DFU. During all clinic visits, the patients’ ulcers will be examined for any changes in the area and depth of the ulcer and microbiological control will be assessed.

 

Steve Parkinson, President & CEO of Lakewood-Amedex, said, “We are very pleased to be embarking upon our second clinical trial in treating DFUs. In our previous experience evaluating Nu-3 for the treatment of patients with infected diabetic foot ulcers, Nu-3 was well-tolerated with no reported adverse events related to treatment. While this previous dose-escalating study was not powered to generate statistically significant efficacy data, it did demonstrate an encouraging efficacy trend. Patients treated with 2% Nu-3 solution for seven days had a 65.5% reduction in ulcer area versus a 29.9% reduction in the placebo arm, as measured 14 days after treatment began. In addition, 62.5% of patients treated with 2% Nu-3 saw a reduction in the microbiological load, versus 20% in the placebo. Now our Phase 2 dose-escalating study will build on the foundation of the previous clinical trials by using a longer treatment duration of 28 days, a higher concentration of 5% followed by 10% Nu-3, as well as an improved Nu-3 gel formulation, all of which we expect will offer a better delivery of Nu-3 and treatment of nonhealing wounds. The impact of both topical and systemic infections remains a tremendous burden on the healthcare system. We believe our commitment to further developing our proprietary, antimicrobial Bisphosphocins technology platform with efficient, localized treatment of serious infections, often caused by antibiotic-resistant pathogens, both gram-positive and gram-negative, will enable healthcare providers to more safely and effectively address a host of bacterial infections that are currently proving challenging using conventional approaches.”

 

“Dr. Felix Sigal, who is one of the most distinguished specialists in the field of diabetic limb salvage, is on staff at both the Hollywood Presbyterian Medical Center and the California Hospital Medical Center. He focuses on wound care and diabetic limb salvage, while pursuing his interest in clinical research to enable better treatment options for his patients. We are pleased to report that Dr. Sigal has now enrolled the first patient in this Phase 2 study evaluating the use of Nu-3 gel in the treatment of diabetic foot ulcers,” said Sumita Paul, MD, MPH, MBA, Chief Medical Officer & Senior Vice President of Research & Development at Lakewood-Amedex Inc. “There will be 12 patients treated with the Nu-3 gel in each of the two cohorts and with a smaller placebo treated group.”

 

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held, clinical stage pharmaceutical company developing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins. The company’s products and technology are covered by an extensive patent portfolio consisting of granted and/or issued patents and pending patent applications covering many major pharmaceutical markets. The company’s lead therapeutic candidates are novel synthetic broad-spectrum antimicrobials proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and all fungal strains tested. Nu-3 has already completed a Phase 2a clinical trial in patients with infected diabetic foot ulcers. For more information, https://lakewoodamedex.com.

 

This press release contains forward-looking statements that can be identified by terminology such as “expects,” “potential,” “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.

 

Contacts
Tiberend Strategic Advisors, Inc.

 

Investors
Lisa Sher
lsher@tiberend.com

 

Media
Dave Schemelia
dschemelia@tiberend.com

 

SOURCE Lakewood-Amedex Inc.

 

This article was originally published here

Chuan Guan Ng 1, Cherry Ya Wen Cheong, Wan Chin Chan, Sean Wei Loong Ho, Melissa Susan Li Ann Phua, Khalid Anuar

 

Abstract
Introduction: Identifying peripheral arterial disease (PAD) during diabetic foot screening (DFS) is crucial in reducing the risk of diabetic foot ulcerations and lower limb amputations. Screening assessments commonly used include absolute systolic toe pressure (ASTP) and toe-brachial index (TBI). There is a lack of research defining the threshold values of both assessment methods. We aimed to compare the accuracy of ASTP and TBI and establish optimal threshold values of ASTP and TBI with reference to the internationally accepted ankle-brachial pressure index (ABPI) screening test, for a multiethnic diabetic population in Singapore.

 

Methods: A retrospective, observational study of DFS results from January 2017 to December 2017 was conducted. Receiver operating characteristic analysis was conducted for ASTP and TBI using the internationally accepted ABPI cut-off value of ≤0.9 to indicate PAD.

 

Results: A total of 1,454 patients with mean (standard deviation) age of 63.1 (12.4) years old were included. There were 50.8% men and 49.2% women, comprising 69.7% Chinese, 13.5% Indian, 10.1% Malay and 6.7% other ethnicities. Areas under the curve for ASTP and TBI were 0.89 (95% confidence interval [Cl] 0.85-0.94) and 0.94 (95% Cl 0.90-0.98), respectively, and the difference was statistically significant (P<0.001). Derived optimal threshold values to indicate ABPI≤0.9 for ASTP and TBI were <95.5mmHg (specificity 0.86, sensitivity 0.84) and <0.7 (specificity 0.89, sensitivity 0.95), respectively.

 

Conclusion: ASTP or TBI may be used to detect ABPI-determined PAD in DFS. The optimal threshold values derived from a multiethnic Asian diabetic population were <95.5mmHg for ASTP and <0.7 for TBI.

This article was originally published here

KOVE Inc. to Distribute the MolecuLight Product Suite to Large South Korean Wound Care Market

 

Toronto, CANADA and Seoul, SOUTH KOREA – (April 6, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, and KOVE Inc., announce that the MolecuLight i:X® device has successfully received regulatory clearance and is now commercially available to the wound care market in South Korea. In addition, the MolecuLight device has also received reimbursement in Korea from the Ministry of Health and Welfare enabling clinician reimbursement for performing the medically necessary MolecuLight procedure.

 

Reimbursement for the MolecuLight procedure was granted by the Ministry of Health and Welfare of Korea, as per the notification number 259-858. This was announced based on Reimbursement data from the Korea New Medical Technology – Stability and Effectiveness Evaluation.

 

MolecuLight is exclusively distributed in South Korea by KOVE, Inc., a company specializing in providing novel products that assist in the treatment of diabetic foot ulcers in Korea including medical devices that assist with the diagnosis and treatment of wounds. KOVE’s team of clinical and technical support specialists have more than 30 years of experience in medical devices and wound care. KOVE also performs clinical research with many university hospitals in Korea.

 

The South Korean market for wound care is significant and can be understood through the pervasiveness of diabetes and diabetic foot ulcers. There are over 5 million Koreans with diabetes1, or 1 diabetic in every 30 adults. 25% of all diabetics also have a diabetic foot ulcer.

 

“The market for the MolecuLight device is significant in South Korea as there is a comprehensive and progressive health care system that quickly adopts new and clinically useful technologies”, says JUNHYOUNG LEE, CEO of KOVE, Inc. “Because of the high national insurance coverage for medical procedures, Korean patients readily visit hospitals to treat ailments and physicians are motivated to treat and monitor wounds until they are fully healed. The MolecuLight technology provides real-time actionable information on wound bioburden and allows clinicians to make bedside decisions quickly. It will be well-received by the South Korean medical community. Significant demand for the MolecuLight device has been verified through market research conducted over the last 12 months as part of the registration and reimbursement process.”

 

“We are most impressed with KOVE, Inc., with their very experienced and responsive team and with their close relationship with the wound care community in South Korea”, says Anil Amlani, MolecuLight’s CEO. “We believe that the speed with which the MolecuLight i:X received both registration and reimbursement shows the quality of our clinical evidence and the proven clinical outcomes that clinicians can achieve using the MolecuLight device. We are confident that South Korea will become a major market for MolecuLight”.

 

MolecuLight’s broad body of clinical evidence includes 55+ peer-reviewed publications, including over 1,400 patients under study, showing the significant benefit of the MolecuLight i:X® to wound care clinicians in all care settings.

 

To request a quotation or a clinical demonstration of the MolecuLight i:X in South Korea, please email junhglee1211@gmail.com or call +82.55.384.2600.

 

References:
1Korea National Statistical Office

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

About KOVE, Inc.
KOVE, Inc. is a company specializing in the diagnosis and treatment of diabetic foot ulcers and wound-related medical devices. It has been conducting continuous clinical research and presentations with many university hospitals in Korea.

 

For more information, contact:

Rob Sandler                                                  JUNHYOUNG LEE

Chief Marketing Officer                             CEO

MolecuLight Inc.                                          KOVE, Inc.

T. +1.647.362.4684                                     Tel: 82.55.384.2600

rsandler@moleculight.com                       junhglee1211@gmail.com

www.moleculight.com                               http://kovekorea.com/

1. https://moleculight.box.com/s/03xcwbw0lwd777yt8jyy50bl72w3cbv4
MolecuLight i:X being used by 2 wound care clinicians on 2 patients in a wound care centre to assess whether their patients’ wounds have elevated bacterial burden.

2. https://moleculight.box.com/s/jbbcbb3hx8pmtbykl2vqkp3q11r6065m
MolecuLight i:X also has the benefit of engaging patients in their own wound care.

New paradigms and advances in medical and translational science are often found at the boundaries of knowledge where multiple disciplines overlap. The ability to examine an issue or problem from a novel perspective may lead to insights and solutions not previously considered. Inflammation, both its mechanism and treatment, is a core tenet of wound research and is also central to a variety of dermatological conditions which are often encountered in the wound care setting … read more

With two more indications approved by the FDA in 2021, hyperbaric oxygen (HBO) therapy continues to gain wide acceptance as an adjunct modality for problematic wounds. During the 2021 Symposium on Advanced Wound Care fall meeting, Jayesh B. Shah, MD, the president of South Texas Wound Associates, in San Antonio, shared the top 10 things that every provider should know about HBO therapy. They include the differences between topical and systemic HBO therapy, as well as various indications, contraindications and side effects … read more

Pressure ulcers, better known as decubitus or bedsores, come across as injuries to the skin as well as the underlying tissue that is an outcome of skin being subject to prolonged pressure. They generally occur on the bony parts like the buttocks, elbow, back, ankles, heels, and shoulder. Those not able to move are more prone to pressure ulcers. If identified at early stages, sepsis, cellulitis, joint and bone infections, or cancer could be prevented, as stated by Persistence Market research in its latest market study entitled “Pressure Ulcer Devices Market”. This is where pressure ulcer devices play an active role … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Pressure injuries are common among patients who experience extended exposure to pressure on a bony prominence or shear to areas of poor turgor, two factors that lead to constriction of a patient’s blood supply to the exposed area. A patient who is bedridden or has certain chronic conditions, such as diabetes,1 is more likely to develop a pressure injury. When mechanical force is imposed on the skin, it can result in poor blood flow and damage to the bone-muscle interface, thus making tissue sensitive and painful. For patients with limited mobility, this can be especially frustrating because they may not be able to adjust positions or medical equipment. If pressure injuries are left untreated or unnoticed, they can also become infected and even enter muscle and bone. Risk assessment tools are available to assess pressure injury risk and can work in tandem with practice standardization, thereby leading to effective treatment plans for practitioners and patients … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Lessons Learnt From a National Referral Hospital in Indonesia

 

Abstract
Background: Diabetic foot ulcer (DFU) is one of the most terrifying diabetic complications for patients, due to the high mortality rate and risk for amputation. During the COVID-19 pandemic, many diabetic patients limited their visits to the hospital, resulting in delays for treatment especially in emergency cases.

 

Objective: This study aimed to compare the characteristics of patients with DFU pre- and during COVID-19 pandemic period. Methods: This study was a retrospective cohort study using foot registry data. We compared our patients’ characteristics pre-COVID-19 pandemic period (1 March 2019-28 February 2020) and during COVID-19 pandemic period (1 March 2020-28 February 2021).

 

Results: Cohorts of 84 and 71 patients with DFU pre- and during COVID-19 pandemic period, respectively, were included in this study. High infection grade (66.7% vs 83.1%, P = .032), osteomyelitis event (72.6% vs 87.3%, P = .04), leukocyte count (15 565.0/μL vs 20 280.0/μL, P = .002), neutrophil-to-lymphocyte ratio (7.7 vs 12.1, P = .008), waiting time-to-surgery (39.0 h vs 78.5 h, P = .034), and number of major amputation (20.2% vs 39.4%, P = .014) were significantly higher during the COVID-19 pandemic period.

 

Conclusion: During the COVID-19 pandemic, patients with DFU had more severe infection, higher proportion of osteomyelitis, longer waiting time for getting surgical intervention, and higher incidence of major amputation.

 

Keywords: COVID-19; amputation; diabetic foot ulcer; infection; mortality; waiting time to surgery.
… from PubMed

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

A person formerly incarcerated at the Allegheny County Jail has filed a lawsuit against multiple members of the jail’s medical staff alleging that a lack of medical treatment in the facility led to the amputation of his leg … In 2011, McCray was shot in the spine, which caused him to lose one of his kidneys and develop a drop foot, which due to dragging of the foot and numbness, made him more susceptible to developing ulcers on his foot, the lawsuit said … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

86 year old female Ankle Wound – Pyoderma Gangrenosum After four years of treating using Santyl, honey, silver products, alginates, Aquacel Ag, Bactroban, sharp debridement, etc. Positive biopsy for PG, Autoimmune disease (lupus) common comorbidity associated with PG A home health, wound-care nurse treated 1.5 years Patient now self-treating Occasional visit to rheumatologist 40 mg of oral steroids Wound healed in only 5 months with Pure&Clean

RedDress, a Florida-based Israeli medical company is shipping revolutionary blood-clotting wound care systems to Ukraine to help with serious injuries and severe trauma wounds … RedDress began shipments of 400 of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as a result of the indiscriminate Russian attacks … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Kristin Fuller, MD
Mr. K. was a 37-year-old male who I saw in my clinic for uncontrolled type-2 diabetes. Every time he came in, his HbA1c and rapid glucose were off the charts. He had multiple hospital admissions for diabetic ketoacidosis, and already had two toes amputated due to severe peripheral arterial disease, a known diabetes complication … One day, a surgeon called to inform me that Mr. K. was in the hospital and would be undergoing a below-the-knee amputation (BKA) due to extremely poor circulation as a result of poor glycemic control. The surgeon initially tried to blame me for not having my patient on the proper diabetic regimen. I explained that I had consistently tried to work with Mr. K., and he was stubbornly non-compliant with his diet and insulin regimen … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Results from a Phase 3, Multicentre, Randomized, Active-controlled, Parallel-group Study

 

Diabetic foot ulcer (DFU), if untreated, accounts for lower-limb amputations affecting patients’ quality-of-life. Diperoxochloric acid (DPOCL) is known to heal DFU by its antibacterial and fibroblast stimulating activity. This was a phase 3, multicentre, randomized, double-blind, active-controlled, parallel-group study conducted to evaluate the efficacy and safety of topic solution of DPOCL compared with isotonic sodium chloride solution (ISCL). Adult patients with type 1 or 2 diabetes with random blood glucose levels of <250 mg/dL, with ≤ than three full-thickness foot ulcers were enrolled. Primary efficacy endpoint was complete wound closure and secondary was wound surface area. Adverse events were analyzed as safety endpoint. Of 311 enrolled patients, 289 were randomized … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Chronic Diabetic Foot Ulcers through Modifications of Infection, Angiogenesis, Macrophage Phenotype and Neutrophil Response

 

This work aimed to evaluate the adjuvant treatment to surgical debridement using topical applications of Lactiplantibacillus plantarum ATCC 10241 cultures in complicated diabetic foot ulcers as compared to diabetic foot ulcers receiving surgical wound debridement. A randomised controlled trial was performed involving 22 outpatients with complicated diabetic foot ulcers that either received surgical debridement (SuDe, n = 12) or surgical debridement plus topical applications of L. plantarum cultures (SuDe + Lp, n = 10) every week during a 12 week treatment period. Compared to patients receiving SuDe, patients treated with SuDe + Lp exhibited significantly increased fibroplasia and angiogenesis, as determined by Masson’s trichrome staining and the study of CD34 cells, α-smooth muscle actin to semi-quantify vascular area, number of vessels and endothelial cells. In addition, a promotion of the polarisation of macrophages from M1 (CD68) to M2 (CD163) phenotype was observed in SuDe + Lp patients with remarkable differences in the tissue localisation … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB

 

A new phase 3 trial assessing a novel topical gel for the treatment of young patients with epidermolysis bullosa (EB) wounds show the birch bark-based product achieved nearly 50% heal of targeted wounds over 12 months … The interim EASE findings, presented in a late-breaking session at the American Academy of Dermatology (AAD) 2022 Annual Meeting in Boston, show birch triterpenes (Oleogel-S10) may provide a unique and broadly-applicable benefit for patients with rare, often deadly skin condition … In an interview with HCPLive at AAD 2022, study author Dedee F. Murrell, MD, director of dermatology at St. George Hospital, USNW, discussed the clinical history of Oleogel S-10 leading … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

chronic wounds proven by gold-standard trial

 

Comparative clinical trial shows significant improvement in wound closure and infection control based on treatment with the plasmajet kINPen® MED from neoplas med compared to best practice wound care – cost-effectiveness analysis proves high cost-savings by innovative technology

 

GREIFSWALD, Germany and FELDKIRCH, Austria, March 22, 2022 /PRNewswire/ — The results of a randomized controlled trial (RTC) may offer new opportunities for the approximately two million patients with chronic wounds solely in Germany: The innovative cold atmospheric plasmajet (CAP-jet) technology showed significantly more healing progress in chronic wounds in comparison to best practice (BP) modern wound care at two study centers. Within six weeks, 59 percent of all wounds healed completely under cold plasma treatment compared to only 5.1 percent in patients under BP therapy. Time to complete healing was also considerably shorter under CAP-jet treatment, and wound infections were overcome statistically significant more rapid. With a very good tolerability profile, an economic analysis of the study data also showed a cost saving of 65 percent for the dressing material alone compared to the BP group. The study data were recently published in the journal Nature Scientific Reports.

 

Acceleration of wound healing and wound closure proven

In the study conducted by Prim. Univ.-Professor Robert Strohal, head of the Department of Dermatology and Venereology at the Federal Academic Teaching Hospital Feldkirch, the cold plasma procedure of the Greifswald-based company neoplas med GmbH was scientifically examined in wound care. For this purpose, he compared treatment with the CAP-jet kINPen® MED at the Austrian Federal Academic Teaching Hospitals Feldkirch and Bregenz with current best practice treatment in 78 patients with infected and non-infected wounds. ‘This study was the first to investigate the exclusive effect of tissue accessible cold plasma on wound healing and infection control without the use of an additional standard therapy,’ said Prim. Univ.-Prof. Strohal.

 

After treatment with the CAP-jet, the proportion of healthy tissue increased significantly faster than under the BP treatment and the wounds under CAP-jet therapy also healed significantly faster. At the end of the study, the wound area in the CAP group had reduced by 94.7 percent compared to the baseline value, in the comparison group it was only 56.3 percent. CAP also proved superior in terms of infection control. In contrast to BP therapy, all wounds infected at the start of the study showed complete resolution of infection signs. In addition, the signs of infection disappeared significantly faster under cold plasmajet therapy.

 

Patients’ quality of life can improve

Ulrike Sailer, CEO of the company neoplas med GmbH in Greifswald/Germany, explained: ‘The Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA) as the central decision-making body of the German health care system already recognized last year the potential of cold plasma for the innovative treatment of chronic wounds at our request. Therefore, the G-BA decided to carry out an observational trial for testing with the aim of obtaining health insurance approval. The results of the clinical trial that now have been published clearly demonstrate the superiority of the CAP-jet kINPen® MED compared to BP wound care. These results provide further evidence for the high clinical relevance of the CAP-jet precision technology. At the same time, it represents important news for millions of people who suffer from chronic wounds for years.’

 

Chronic wounds are often associated with high morbidity and considerable impairments in everyday life as well as the patients’ psyche. Faster wound healing and thus a shorter therapy duration by using the plasmajet kINPen® MED can therefore significantly improve the patients’ quality of life. Furthermore, a lower burden by pain during treatment can be observed, and a reduced number of dressing changes can be assumed. Patients confirmed the very good tolerability and even described the treatment as pleasant in the majority of cases.

 

Significant advantage in treatment costs

A cost-effectiveness analysis based on the available study data showed that 21.4 percent fewer physician visits and 34.3 percent fewer dressing changes were necessary in the CAP-jet group compared to BP. The savings alone in dressing material resulted in a cost advantage for CAP-jet therapy of 64.7 percent compared to BP. Previously, average costs of 10,000 € per patient and year were assumed. Ulrike Sailer: ‘Thus, the cold plasmajet kINPen® MED offers not only a more efficient and tolerable technology, but also opens up the opportunity for significantly higher cost-effectiveness in the treatment of chronic wounds.’

 

Further information material can be found under the following link: https://1drv.ms/u/s!Aph6cOwNbPEJgQCIbClSETCZ_lal?e=BvkuGi

 

Background Information:

The study included 78 patients with wounds up to 10 x 20 cm in size and existing for at least 6 weeks. The patients were randomized in a 1:1 ratio into two groups and treated for the study duration of 6 weeks either with the CAP-jet kINPen® MED (30 seconds per cm2 wound area) or suitable wound dressings according to BP wound care. Only one wound per patient was evaluated.

 

With regard to the treatment regime, CAP-jet therapy was administered 3 times in the 1st week in the CAP group, 2 times in the 2nd week and once a week in the following observation period; furthermore, the wounds were covered with gauze and a secondary dressing. In contrast, the BP group was treated with a wound phase-adapted dressing; infected wounds were additionally cleaned with an antiseptic. In both groups, patients with venous ulcers received compression therapy. The primary endpoint of the study was the amount of granulation tissue at the end of the study. In addition, cold plasma effects on wound infection, wound area, healing time, wound pH and exudate volume (wound fluid) as well as local tolerability were investigated.

 

Improvement in wound infection: All 13 wounds infected at baseline in the CAP-jet group showed complete resolution of infection signs without the need for additional antiseptics. In contrast, 4 of the 18 wounds infected at baseline in the BP group showed no improvement despite the use of antiseptics. Furthermore, the signs of infection decreased significantly faster under CAP-jet therapy compared to BP therapy. These data confirm the previously published evidence on the good antimicrobial efficacy of CAP.

 

Cold plasma is a gas containing ionized atoms, ions and electrons that has been shown to disinfect wounds and activate the wound healing process. With its fine jet, the plasmajet kINPen® MED enables highly precise treatment in anatomically and pathologically challenging areas under visual control and without touching, which is not possible with other wound therapies.

 

About neoplas med GmbH

neoplas med GmbH was founded in 2009 as a spin-off of the Leibniz Institute for Plasma Science and Technology e. V. (INP) in Greifswald, Germany. Ulrike Sailer took over the position of managing director at the end of 2019. Based on the INP research into plasma medicine, the emerging company develops innovative products for medical applications. The first product developed on this basis is the CE-marked kINPen® MED atmospheric pressure plasmajet, the first internationally approved and marketed plasmajet for the treatment of chronic wounds and pathogen-induced skin disorders. It is the result of a long-lasting cooperation with the INP institute, the university hospital of Greifswald, Germany, the Charité hospital of Berlin, Germany, and various industrial partners. In July 2021, the Federal Joint Committee, as the central decision-making body in the self-governing health care system, decided on a trial study with the cold plasmajet procedure and thus took an important step towards reimbursement by the health insurance companies.

 

About kINPen® MED

The plasmajet kINPen® MED is the first atmospheric pressure plasmajet to receive CE approval for the treatment of chronic wounds and pathogen-induced skin disorders. The plasmajet applies a physical cold plasma with a temperature of < 40 degrees Celsius with pinpoint precision and without wound contact. Areas with an uneven profile, recesses or cavities can be reached easily and treated evenly. The noble gas argon used for the generation of the plasma provides a controlled atmosphere around the generated plasma beam, thus ensuring a consistent high treatment quality.

 

Press contact

Claudia Kerber
Phone: +49 3834 515 201
Mobile: +49 (0)162 23 770 70
claudia.kerber@neoplas-med.eu
neoplas med GmbH
Walther-Rathenau-Straße 49a, 17489 Greifswald, Germany

By Chase Doyle
If untreated or unsalvageable, the diabetic foot requires surgical interventions to address the risks to its viability. However, recent advancements in the field suggest that surgeons may not always have to sacrifice a limb to save a life.

During the 2021 virtual American College of Surgeons Clinical Congress, Lucas M. Ferrer, MD, described the use of endovascular venous arterialization for limb salvage, and William P. Robinson, MD, discussed the timing of foot amputation after revascularization … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population

 

OCEANSIDE, Calif., March 23, 2022 /PRNewswire/ — Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have achieved such a designation and allowing the company to now commence marketing in China with its local partner.

 

China has the world’s largest Diabetic and resultingly Diabetic Foot Ulcer (DFU) population. The International Diabetes Federation estimates that 10.6% of the Chinese adult population now have diabetes that equates to 141 million people. This represents a 56%, or 50 million person, increase in the last 10 years alone.1 In China, the annual incidence of DFU and Amputation has recently been reported to be 8.1% and 5.1% respectively, representing a staggering 11.4 million ulcerations and 7.2 million preventable lower extremity amputations every year.2

 

AOTI’s globally patented TWO2 homecare therapy has been demonstrated in recently published high-quality Randomized Controlled Trial 3 and Real Word Evidence 4 studies to provide more durable complete DFU healing. Resulting in six-fold reductions in ulcer recurrence, with an unprecedented 88% reduction in hospitalizations and 71% reduction in lower extremity amputations seen over 12 months. Such sustained healing provides patients with renewed hope of limb preservation, while offering significant reductions in healthcare resource utilization with resultant health economic savings.

 

Professor Andrew Boulton, past-President of the European Association for the Study of Diabetes and Professor of Medicine at the University of Manchester, UK and University of Miami, USA, and Chairman of AOTI’s Scientific and Clinical Advisory Board, commented: “Diabetes is one of the fastest growing global health emergencies of the 21st century. It is a real game-changer to finally have clinically proven homecare therapeutics like TWO2 available that make meaningful impact in such critical outcomes as hospitalizations and amputations. Now that TWO2 therapy is authorized in China, the world’s largest diabetic foot ulcer population has a renewed hope for better outcomes.”

 

1 International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

 

2 Development and validation of a brief diabetic foot ulceration risk checklist among diabetic patients: a multicenter longitudinal study in China. Zhou, Q., Peng, M., Zhou, L. et al. Nature, Sci Rep 8, 962 (2018). https://doi.org/10.1038/s41598-018-19268-3

 

3 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

 

4 Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

 

About AOTI
AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented non-invasive Topical Wound Oxygen (TWO2) homecare therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

 

For more information see: www.aotinc.net
Dr. Mike Griffiths
CEO & President
332487@email4pr.com
(760) 672 1920
SOURCE AOTI Inc.

Janet Falade, PharmD Candidate, South College School of Pharmacy

 

The increased risk of having type 2 diabetes (T2D) and cardiovascular disease (CVD) has been a significant concern in the health care sector worldwide. Also, it has been regularly reported by the World Health Organization (WHO) that cardiovascular diseases (CVDs) and diabetes mellitus are part of the ten major leading causes of death globally. Some changes, such as increased blood pressure, cholesterol, and blood sugar level, are usually apparent before the onset of these diseases. Therefore, early detection of individuals at increased risk of having this disease is essential in preventing the disease Incidence. Furthermore, these diseases can influence specific measures like lifestyle changes such as healthy diet and exercise. In addition, machine learning models can help predict the risk of having T2D and CVD. Other factors such as lipid level and blood sugar levels, particularly evaluation of gene variations, protein complements, and metabolome, which includes lipidome, may aid in identifying physiopathology pathways that might be … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Debridement is the process of removing nonviable tissue and foreign objects (such as glass or shrapnel) from a wound bed to help the wound heal.1 Decaying tissue can trap bacteria and lead to a harmful infection such as gangrene, which is the death of body tissue resulting from a lack of appropriate blood flow or in response to a severe bacterial infection.2 Debridement is thus critical to effective wound management … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Antimicrobial Action, and in vivo Effect for Enhancing Wound Healing in Diabetic Rats

May Almukainzi, Thanaa A El-Masry, Walaa A Negm, Engy Elekhnawy, Asmaa Saleh, Ahmed E Sayed, Mohamed A Khattab, Dalia H Abdelkader

Download full article (PDF)

Purpose: Gentiopicroside (GPS), an adequate bioactive candidate, has a promising approach for enhancing wound healing due to its antioxidant and antimicrobial properties. Its poor aqueous solubility negatively affects oral absorption accompanied by low bioavailability due to intestinal/hepatic first-pass metabolism. Our aim in this study is to fabricate GPS into appropriate nanocarriers (PLGA nanospheres, NSs) to enhance its solubility and hence its oral absorption would be improved.

 

 

Methods: Normal and ODS silica gel together with Sephadex LH20 column used for isolation of GPS from Gentiana lutea roots. Crude GPS would be further processed for nanospheres fabrication using a single o/w emulsion solvent evaporation technique followed by in vitro optimization study to examine the effect of two formulation variables: polymer (PLGA) and stabilizer (PVA) concentrations on the physical characterizations of prepared NSs. Possible GPS-PLGA chemical and physical interactions have been analyzed using Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC). The optimum GPS-PLGA NSs have been chosen for antimicrobial study to investigate its inhibitory action on Staphylococcus aureus compared with unloaded GPS NSs. Also, a well-designed in vivo study on streptozotocin-induced diabetic rats has been performed to examine the wound healing effect of GPS-PLGA NSs followed by histological examination of wound incisions at different day intervals throughout the study.

 

 

Results: The optimum GPS PLGA NSs (F5) with well-controlled particle size (250.10± 07.86 nm), relative high entrapment efficiency (83.35± 5.71), and the highest % cumulative release (85.79± 8.74) have increased the antimicrobial activity as it exhibited a higher inhibitory effect on bacterial growth than free GPS. F5 showed a greater enhancing impact on wound healing and a significant stimulating effect on the synthesis of collagen fibers compared with free GPS.

 

Conclusion: These findings demonstrate that loading GPS into PLGA NSs is considered a promising strategy ensuring optimum GPS delivery for potential management of wounds … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

North Texas researchers hope their development will help ward off diabetic foot ulcers, which can lead to amputation.
Research scientists at The University of Texas at Arlington have developed footwear technology that may prevent the development of diabetic foot ulcers … People with diabetic neuropathy deal with numbness in their legs and feet and are often unable to detect and respond to stress-related pain by adjusting their foot loading … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

by Richard Payerchin
Work-life balance is the most important factor for new physicians choosing their first jobs – possibly as a result of dealing with stresses brought on by COVID-19, according to a new survey … The responses confirmed and surpassed a similar finding from a study of 2018, according to health staffing consultant CHG Healthcare. The company announced the survey from its CompHealth division, which surveyed 145 physicians who had been out of residency for two to three years … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

TAMPA, Fla., March 16, 2022 /PRNewswire/ — Leading wound care management and clinical services provider, WoundGenex, today announced a strategic partnership with MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX”), a transformational placental biologics company, to launch an exclusive version of WoundGenex’s Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.

 

WoundGenex Partners with MIMEDX to Launch the first-of-its-kind Premier Graft Program.
The partnership adds the portfolio of MIMEDX advanced wound care products to the list of treatment options available to clinicians who rely on WoundGenex’s expertise in clinical documentation requirements, wound care revenue cycle, and reimbursement policies. Premier Graft Program members tap into group purchasing power that allows WoundGenex to facilitate product ordering at no upfront cost to the provider or organization. WoundGenex Program Liaisons work with providers and billing specialists to help streamline the entire process, including proper utilization of products, documentation of medical necessity, coding, and coding education, and more. A first-of-its-kind program, no payment is due from the ordering providers until reimbursement is realized on the product.

 

MIMEDX is a leading provider of placental allografts in the Cellular Tissue Products/Skin Substitute segment of the advanced wound care category. MIMEDX’s flagship advanced wound care product, EPIFIX®, is covered by 100% of national commercial payors for the treatment of diabetic foot ulcers, totaling over 300 million covered lives.

 

“WoundGenex is thrilled to be able to partner with MIMEDX to introduce a meaningful solution to providers to maximize clinical and reimbursement outcomes. Clinical expertise, industry leading advanced wound care products, and a strong understanding of reimbursement across all sites of service is the key for a successful practice,” said WoundGenex President and Co-founder, Thomas Smith.

 

“In partnering with WoundGenex, we are able to further substantiate our mission to increase access to innovative technologies for patients and customers alike,” said Rohit Kashyap, Ph.D., MIMEDX Chief Commercial Officer. “We are excited for the opportunity this program will provide to ensure more patients receive the care they need, as well as the opportunity to continue strengthening our reimbursement and service offerings for clinicians who choose our products.”

 

About WoundGenex
Founded in 2014 in Tampa, Florida, WoundGenex optimizes the way clinicians provide wound care to their patients in various places of service such as physician practices, hospitals, surgical centers, nursing homes, free-standing wound centers across the country. Thanks to more than two decades of experience in both the clinical and administrative aspects of wound care WoundGenex provides true solutions to help meet the challenges of providing best-in-class care from start to finish – from clinical and operational excellence to financial and procedural optimization.

 

To learn more about WoundGenex and the Premier Graft Purchasing Program, please visit https://woundgenex.com.

 

Media Inquiries: Media@WoundGenex.com

 

About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit https://MIMEDX.com

 

MIMEDX Contacts

 

Investors:
Jack Howarth
Investor Relations
404.360.5681
jhowarth@mimedx.com

 

Media:
Hilary Dixon
Corporate & Strategic Communications
404.323.4779
hdixon@mimedx.com

 

Cision View original content:https://www.prnewswire.com/news-releases/woundgenex-partners-with-mimedx-to-launch-premier-graft-program-to-wound-care-providers-nationwide-301503626.html

 

SOURCE WoundGenex

by Teresa Carvalho MSc
The pivotal Phase 3 VIITAL clinical trial of EB-101, Abeona Therapeutics’ experimental cell therapy for wound healing in people with recessive dystrophic epidermolysis bullosa (RDEB), has met its enrollment target.

The company also announced that top-line results from the VIITAL trial (NCT04227106) are expected in the in third quarter of this year … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New Orleans, LA
March 24 – March 27
Astor Crowne Plaza
Brochure

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

To understand the concepts of a wound and wound healing, we must examine the skin and its pathophysiology, as well as its unique structures and functions. Skin care and wound management must be grounded in a comprehensive knowledge base of the structure and functions of the skin. The skin is the largest organ of the body, covering approximately 18 square feet and weighing about 12 pounds, or up to 15% of total adult body weight. It requires one-third of an individual’s circulating blood volume to sustain it. Normal surface skin temperature is 92 degrees, compared with a core body temperature average of 98.6 degrees … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Manesh Patel MD, Christopher Granger MD and Larry Allen MD

 

One thing that you mentioned about risk factors is interesting, and I’m going to ask Larry, how do you usually think about comorbidities, including heart failure? I tell our fellows in clinic, if the patients don’t smoke and don’t have diabetes, those are overrepresented in PAD [peripheral artery disease]. This comes from data that are a bit older, but the PARTNERS study where they evaluated patients doing an ABI [ankle-brachial index] in primary care clinics, about 7000 patients, and they found that a quarter of them had PAD. If they were 50 years old and over, they tested whether they had diabetes and tobacco use, or over 70. Unrecognized PAD probably exists in about a quarter [of patients] in our primary care clinics, and it fits with these comorbidities … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Diabetic foot ulcers can be extremely challenging to treat and are associated with a high morbidity and mortality. A recent large randomised controlled trial (RCT), undertaken in the US, found that a single application of a fetal bovine acellular dermal matrix plus standard of care (SOC) is a faster and more effective treatment for these ulcers than SOC alone. This masterclass will explore this evidence base and debate how to optimise use of this dermal scaffold for this indication.

 

Wed, Mar 23, 2022 · 2:00 PM · EDT

 

John C. Lantis II
Chief of Surgery, Mount Sinai West Hospital

register

Michael S. Miller DO, • Lindsey Markey RN, BSN • Regina Yoder RN • Kevin Powers DPM• TCC Kits provided by M-Med

 

Introduction:
It is well stated in the literature that Total Contact Casting (TCC) is a standard of care for off-loading of neuropathic ulcers of the plantar surface. Another standard of care is to provide a moist wound healing environment. Evidence to support appropriate wound dressings under TCC is currently unavailable despite recognition that the wound environment and thus the amount of drainage changes as the wound progresses towards healing. This pilot case series of three patients with plantar based diabetic neuropathic ulcers uses two dressings, a five layer silicone foam with absorbent polymer and moisture retentive backing dressing (SF)* for low to moderate drainage and a non-adherent super-absorbent (SAP)† polymer dressing for moderate to high exudate levels.

 

Clinical Problem:
Many TCC kits include a generic, open-cell, polyurethane foam dressing (OCF). These dressings do not absorb or retain fluid in a moderate to high exudate environment which can lead to maceration and non-healing. Furthermore, due to the high moisture vapor transmission rate of OCF, wounds with low exudate may experience desiccation and result in the development of slough and biofilm.1

 

Methods:
This pilot case series evaluates the performance of two dressings under a TCC‡. The 1st dressing is a five-layer silicone foam with super-absorbent polymer and moisture retentive backing for low to moderately exuding wounds (SF)*. The 2nd dressing is a non-adherent absorbent (SAP)† polymer dressing for moderate to high exudate levels. A total of 3 Wounds were assessed, cleansed, debrided if necessary, categorized by exudate level, and TCC was applied for 7 days. The expected outcomes were to avoid maceration, increase in healthy granulation/epithelial tissue, and achieve maximum wear time of TCC.

 

Results:
All three of the pilot cases healed completely in acceptable time with no untoward complications. The important feature was that the changes in the amounts of drainage which were identified as the healing progressed were compensated for by changing the dressings based on the amounts of exudate identified. This effectively minimized associated peri-wound maceration, damage to the increasing granulation tissue and improved tolerance of their feet to the total contact casting.

 

Conclusion:
TCC kits should consider including dressings for low-moderate and moderate-high exudate and cease adding the one-dressing-fits-all generic foam into the kit. Additionally, although foam dressings are lumped into single category, their individual traits such at total volume handling, exudate retention, and MVTR have erratic variation in function. The SF in this case series exceeded expectation and can be a standard of care unless exudate overwhelms the dressing in the 7 day expected wear. At that time, SAP should be used in place of SF to manage high exudate. Our experience is that this combination of dressings progresses wounds towards healing, enhances the clinical benefits and wear time of TCC, and decreases the potential for wound healing complications.

 

Case History 1 45 year old Insulin-dependent diabetic male (IDDM) with a history of poor compliance presented with a plantar ulcer of 2 years duration. He had developed an acute Charcot’s Arthropathy, misdiagnosed as osteomyelitis and had surgery to remove “infected” bone. He had ongoing significant drainage with periwound skin maceration and no evidence of healing.	Course of Treatment: Aggressive debridement of the ulcer was performed with identified bone at the base of the ulcer. However, further workup did not demonstrate osteomyelitis. He was placed in a TCC and SAP used due to concerns about the excessive drainage. With the drainage controlled, maceration resolved and offloading successfully managed, he went on to heal completely.
Case History 2 64 year old IDDM with a history of a Diabetic Neuropathic foot ulcer of the plantar heel. He had undergone surgery years before leaving him with a soft tissue deformity predisposing him to recurrent ulcers.	Cource of Treatment An aggressive debridement was performed with no bone exposure noted. He had moderate serous drainage from the ulcer and so SF was used to control the drainage without creating a dry wound base. TCC was performed weekly with changes of the SF dressing. With the drainage controlled and offloading accomplished, he went on to heal completely.
Case History 3 A 64 year old female with advanced rheumatoid arthritis and foot deformity presented with a 6 month history of a nonhealing ulcer of the right plantar foot. A surgery to correct this had incisional dehiscence. Topical dressings and an offloading boot were previously used unsuccessfully.	Course of Treatment An aggressive debridement was performed with no bone exposure noted. Her significant serous drainage was treated with SAP and TCC applied weekly for offloading. Over the next several weeks, the drainage decreased and the dressing was changed to SF due to decreasing wound drainage. With the drainage controlled and offloading in place, she went on to heal completely.

References
1. Hurlow J, Couch K, Laforet K, Bolton L, Metcalf D, Bowler P. (2015) “Clinical Biofilms: A Challenging Frontier in Wound Care”. Adv Wound Care (New Rochelle) 4(5): 295–301.
* KerraFoam is a registered trademark of Crawford Woundcare Ltd. † KerraMax Care is a registered trademark of Crawford Woundcare Ltd.
‡ Total Contact Casting Kits by M-Med, Mebane, NC., supplied at no charge for this case series.
This poster abstract is funded and supported by Crawford Healthcare Inc.
© Copyright Crawford Healthcare Ltd, 2016. This literature and product report is supported and funded by Crawford Healthcare Ltd. 2016

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Researchers at the Royal College of Surgeons in Ireland (RCSI University of Medicine and Health Sciences, along with collaborators in Germany and Switzerland, say their work has revealed new information about how blood clots are formed during wound healing. Their study “Platelets drive fibronectin fibrillogenesis using integrin αIIbβ3”, which appears in Science Advances, examines the behavior of platelets at a wound site, specifically their ability to sense where within a blood clot they are and remodel their surroundings accordingly … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

A team led by Maria Leptin has shown in the fruit fly Drosophila that autophagy, a mechanism of stress responses in cells, plays an important role in wound healing: When a wound heals, the process of autophagy is initiated and regulated by the protein complex TORC1. This is a newly discovered function of autophagy and the first evidence that autophagy controls the formation of syncytia (multinucleated cells). While syncytia are also formed during the development of muscles or the placenta, their role in wound healing and the involvement of autophagy are new discoveries. The article, ‘Autophagy-mediated plasma membrane removal promotes the formation of epithelial syncytia’ has been published in The EMBO Journal … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

RedDress, a privately held U.S. and Israel-based wound care company, announced today it has been awarded a group purchasing agreement with Premier Inc. This agreement allows Premier members, at their discretion, access to RedDress’ wound care product, ActiGraft® system … ActiGraft is the first wound care product that enables health care providers to produce—in real time—an in vitro blood clot from a patient’s own blood. Once applied, the blood clot serves as a protective covering and supports the body’s natural wound healing response. ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds, and post-surgical wounds … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

of EB-101 in RDEBTopline data from VIITAL™ expected in the third quarter of 2022
Abeona Therapeutics (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study. The objective of VIITAL™ is to evaluate the safety and effectiveness of Abeona’s investigational EB-101 product for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. Large chronic wounds typically do not heal spontaneously and inflict the greatest pain and clinical burden on RDEB patients. Large chronic wounds treated in VIITAL™ measured greater than 20 cm2 of surface area and had remained open for more than six months. In a phase 1/2a study conducted at Stanford University, large chronic wounds treated with EB-101 showed considerable wound healing and reduction in associated long-term pain for up to six years … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

for Diabetic Foot Ulcer Infections
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”). The patent, entitled “Bismuth-thiol compositions and methods for treating wounds,” extends topical pravibismane patent protection through to mid-2039. The granted claims cover the administration and use of topical pravibismane compositions in diabetic foot ulcer infections. This patent further expands Microbion’s patent portfolio, comprising granted claims to its pravibismane composition and methods of treating wounds and diabetic foot ulcers.

 

“We are pleased that the USPTO has granted this new patent supporting our pravibismane program for the treatment of diabetic foot infections,” said Dr. Brett Baker, Microbion’s President and Chief Innovation Officer. “This patent includes claims built on data from our Phase 1b clinical studies in infected patients. In these studies, topical pravibismane demonstrated a 3-fold reduction in chronic wound size compared to placebo when administered as an adjunct to standard of care treatment in patients with moderate to severe DFI. We are committed to developing novel therapies that fulfill the unmet needs caused by diabetic foot ulcer infections and faced by these patients every day.” … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

by Stephen “Andy” Rohrer, MSN, RN, APRN, AGACNP-BC, FNP-BC, CWS

I practice in West Memphis, Arkansas, about 15 miles from the city of Memphis, Tennessee. The location is suburban but the culture is rural. My people in Arkansas primarily work in farming and “blue collar” industries. West Memphis, Arkansas is separated from Memphis, Tennessee by the Mississippi River. We find that many Arkansans are simply intimidated by even the thought of crossing the bridge to go into Memphis (population about 650,000).

I am fiercely protective of my patients and our way of life here in Arkansas. I know they are hard-working, independent people who often try to fix things themselves; unfortunately, they show up for medical care only when things have progressed to dire circumstances. The drive time for patients to reach me varies from a few minutes to more than 2 hours. Our payer mix is increasingly Medicare Advantage plans … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Pain associated with chronic wounds can affect quality of life and have a major impact on physical, emotional and cognitive function. This module explores the importance of pain management, the mechanism and types of pain, as well as how to assess and manage pain.
Chronic wounds, Pain Management, Quality of life, Wound Care, Wound pain … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New research led by the University of Bristol has found the protein p53 plays a key role in epithelial migration and tissue repair. The findings could improve our understanding of the processes used by cells to repair tissues, and be used to identify interventions that could accelerate and improve wound repair … Epithelial tissues are the linings that protect the body’s external skin and internal cavities, and their ability to repair themself is important. ?It is known that wounded epithelia repair themself thanks to the ability of the remaining cells to start migrating, collectively, to seal the breach. Specialised migratory cells called leader cells … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

WOUND CARE Q&A from Podiatry Today
Windy Cole, DPM, CWSP, Barbara Aung, DPM, DABPM, CWS, FAPWHc, Matthew Garoufalis, DPM, FASPS, FACPM, CWS, FFPM RCPS (Glasg), Brian Lepow, DPM, DABPM, and Eric J. Lullove, DPM, CWSP, DABLES, FAPWHc

 

Over the past several years, artificial intelligence (AI)-based innovation in the medical field has emerged, including in various types of imaging. How might such technology apply to the field of wound care? In this edition of the Wound Care Q & A column, the panelists share their experiences and thoughts on if AI could bring a new era of improved outcomes … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

18-19 May 2022 – Glasgow, UK
We believe that skin health and wound healing is everyone’s business and that change happens when we work together, not in silos.

We believe that skin health and wound healing is everyone’s business and that change happens when we work together, not in silos. Come to our annual face to face conference and you can join our community and listen to live lectures, interviews and discussions, take part in workshops, visit industry exhibition booths, network with colleagues and speakers and join the live conversations during the sessions.

Our conference really is space where professional connections are made, ideas are shared and collaborative action happens … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

Cellular and/or tissue-based products (CTPs) comprise an exciting and emerging technology in wound care. Deep and large wounds require more than just a standard dressing, topical ointments, and time. Wounds that penetrate the reticular dermis and below (deeper than ~0.57 mm) require additional scaffolding to support wound closure and prevent significant scarring.1 CTPs provide this scaffolding as well as naturally occurring chemicals and cells that support wound healing … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.